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Summary: 
This thesis reports the cloning, overexpression and characterization of the 
coaX gene product from Bacillus subtilis and its homologue from Helicobacter 
pylori.  It demonstrates that these proteins have pantothenate kinase activity.  
Compared to the two pantothenate kinase analogues classified to date, these 
two enzymes exhibit distinctly different characteristics, suggesting that they 
are the first characterized examples of a third pantothenate kinase analogue.  
In addition, mutational studies are presented that probe the importance of 
conserved aspartate residues within the active sites of these newly 
characterized analogues. The results show that these residues are important 
for the activity of the protein. 
 
 
 
 
iv 
Opsomming: 
Die klonering, uitdrukking en karakterisering van die coaX geenproduk van 
Bacillus subtillis en sy homoloog van Helicobacter pylori word in hierdie 
werkstuk gerapporteer. Daar word getoon dat beide hierdie twee proteïene 
pantoteensuurkinase aktiwiteit besit. In teenstelling met die twee 
pantoteensuurkinase analoë wat tot dusver bestudeer is, toon hierdie twee 
ensieme duidelik onderskeidende karaktereienskappe. Hierdie verskeinsel 
ondersteun die veronderstelling dat hierdie ensieme die eerste 
gekarakteriseerdie voorbeelde van ’n derde pantoteensuurkinase analoog is. 
Mutasie studies bevestig verder die belang van gekonserveerde aspartaat 
residue binne-in die aktiewe sentrum van die nuut gekarakteriseerde analoog 
en dui aan dat hierdie residue van spesiale belang is vir die aktiwiteit van die 
proteïen. 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my husband, Willem 
 
vi 
Acknowledgements 
 Doctor Erick Strauss, my supervisor, for his constant guidance and 
assistance throughout the duration of my Masters course.  I would also 
like to thank Erick for his friendship, which has come to mean a great 
deal to me over the last couple of years. 
 Prof. Swart, my co-supervisor, for his role in this work.  
 The Chemistry Department for granting me the liberty to conduct my 
research in their department. 
 André Venter for conducting the ESI-MS analysis. 
 Prof. Andrei Osterman for his ever interesting and most helpful 
suggestions. 
 My fellow students, Marianne van Wyk, Lizbé Koekemoer and Jandré 
de Villiers for their invaluable friendship and support.  In particular, I 
would like to thank Marianne for the translation of my summary into 
Afrikaans. 
 Stellenbosch University, the opportunity to study at this remarkable 
institution has been an honour. 
 My sincerest gratitude to my parents for laying the foundation for the 
education that I now possess.  Also for the love and support that they 
have given me throughout my years at Stellenbosch (and before of 
course!).  My brother and sister have also been an undeniable support 
system for which I am very grateful. 
 I would like to thank my husband, Willem, whose support throughout 
this endeavour has been nothing short of remarkable. 
vii 
Table of Contents  
Declaration ii 
Summary: iii 
Opsomming: iv 
Acknowledgements vi 
Table of Contents vii 
Abbreviations xii 
CHAPTER 1 1 
A General Introduction 1 
CHAPTER 2 3 
Coenzyme A, Central to Metabolism 3 
2.1.  The Importance of Coenzyme A: 3 
2.2.  Structure of CoA 4 
2.3.  Function of Coenzyme A 5 
2.3.1.  The Claisen Enzymes 7 
2.3.2.  Acyltransferases 8 
2.3.3.  Other CoA Ester-utilizing Enzymes 8 
2.4.  Biosynthesis of CoA 11 
2.4.1.  Pantothenate in Nutrition 11 
2.4.2.  The Pantothenate Biosynthetic Pathway in E. coli 12 
2.4.2.1.  A General Overview 12 
2.4.2.2.  Biosynthesis in Detail 12 
α-Ketopantoate Biosynthesis 12 
Pantoate Biosynthesis 12 
β-Alanine Biosynthesis 13 
Pantothenate Biosynthesis 15 
2.4.3.  Pantothenate and Transport 15 
2.4.4.  Coenzyme A Biosynthesis From Pantothenate. 16 
2.4.4.1.  Phosphorylation of Pantothenate 17 
viii 
2.4.4.2.  Formation of 4’-Phosphopantetheine 17 
2.4.4.3.  Conversion of 4’-phosphopantetheine to Coenzyme A 18 
2.5.  Regulation of Coenzyme A Levels. 19 
2.5.1.  Compartmentalization of CoA 19 
2.5.2.  Feedback Regulation by Pantothenate Kinase 19 
2.5.3.  Secondary Regulation by CoaD 21 
2.5.4.  Regulation of CoA Levels by Gene Expression 22 
2.5.5.  Regulation by Degradation 22 
2.6.  Coenzyme A as a Drug Target 23 
2.7.  References 24 
CHAPTER 3 31 
Pantothenate Kinase, an Overview 31 
3.1.  Introduction 31 
3.2.  Type I Pantothenate Kinase 32 
3.2.1.  E. coli Pantothenate Kinase, the Prototypical Bacterial PanK 32 
3.3.  Type II Pantothenate Kinase 35 
3.3.1.  Pantothenate from Staphylococcus aureus, an Atypical Type II 
PanK 36 
3.4.  Type III Pantothenate Kinases 37 
3.5.  Type IV PanK in Archaeabacteria 40 
3.6.  Pantothenate Antimetabolites 41 
3.7.  Significance of the Discovery of a Third PanK Analogue 45 
3.8.  References 46 
CHAPTER 4 52 
Characterization of the First Type III Pantothenate Kinase 52 
4.1.  Introduction 52 
4.2. Results and Discussion 55 
4.2.1.  Cloning, Purification and Expression of Type III PanKs 55 
4.2.2.  Complementation 56 
4.2.3.  Kinetic Characterization of Type III PanKs 59 
ix 
4.2.4.  Testing the Efficacy of Alternate Phosphoryl Donors 61 
4.2.5.  Inhibition of Type III PanKs by CoA and Acetyl-CoA 63 
4.2.6.  Effect of Pantothenamide Antimetabolites on Type III PanKs 64 
4.2.7.  Gene Cluster Analysis in Support of Functional Characterization 65 
4.3.  Conclusion 66 
4.4.  Experimental Procedures 67 
4.4.1.  Materials and Methods 67 
4.4.2.  Construction of Expression Vectors 68 
4.4.2.1.  Standard Cloning Procedure 69 
Design of Primers 69 
PCR Reaction 69 
DNA Electrophoresis 70 
Digestions: 70 
Ligation of plasmid and PCR DNA 71 
Transformation 71 
Making Competent Cells: 71 
Transformation Procedure 72 
Screening of Clones 72 
Screening Gel 73 
Digestion Screen 73 
Sequencing 73 
4.4.3.  Complementation Studies 74 
4.4.3.1.  Cloning of the Expression vectors 74 
4.4.3.2.  Complementation 75 
Complementation on Minimal Media Plates: 76 
Complementation in Liquid Media 76 
4.4.4.  Expression and Purification of Recombinant Proteins 76 
4.4.5.  Determination of Kinetic Parameters 78 
4.4.6.  Inhibition Studies 79 
4.4.7.  Testing of Alternate Phosphoryl Donors 80 
4.5.  References 81 
x 
CHAPTER 5 84 
Mutation Studies of the Type III Pantothenate Kinase from H. pylori 84 
5.1.  Introduction 84 
5.2.  Structural Analysis of Kinases 84 
5.3.  Fold predictions for Type I, II and III Pantothenate Kinases 87 
5.3.1.  Type I PanK 87 
5.3.2.  Type II PanK 87 
5.3.3.  Type III PanK 88 
5.3.4.  Hexokinase I – An Example of a Ribonuclease H-like kinase 91 
5.4.  Results and Discussion 94 
5.4.1.  Critical Residues Involved in Enzyme Activity 94 
5.4.2.  Mutational Analysis 95 
5.4.3. Purification of Mutant Proteins 97 
5.4.4.  Activity of CoaX Mutants 98 
5.5.  Conclusion 102 
5.6.  Methods and Materials 103 
5.6.1.  Materials 103 
5.6.2.  Mutant Construction 103 
5.6.3.  Protein Purification 104 
5.6.4.  Pantothenate Kinase Assays 105 
5.7.  References 106 
CHAPTER 6 108 
Concluding Remarks and Future Research Possibilities 108 
6.1.  Summary of Findings 108 
6.2.  Future Research Possibilities 109 
6.2.1.  High KM of Type III PanKs 109 
6.2.2.  Finding Inhibitors for Type III PanK 109 
6.2.3.  Alternate Metal Ions Used by Type III PanK 111 
6.2.4.  Crystal structure of the Type III PanK 113 
6.2.5.  Cloning and Characterization of Additional Type III PanKs. 113 
Thermus thermophilus 114 
xi 
Treponema pallidum 114 
Pseudomonas aeruginosa 117 
6.2.6. Additional mutation studies 117 
6.2.7. Drug Design 118 
6.2.8.  The Role of CoaX Proteins 119 
6.3.  References 120 
 
xii 
Abbreviations 
A  Absorbance 
ACP  Acyl carrier protein 
ADP  Adenosine diphosphate 
AMP  Adenosine monophosphate 
APS  Ammonium persulphate 
Asp  Aspartate 
ATP  Adenosine triphosphate 
Bs  Bacillus subtilis 
BSA  Bovine serum albumin  
CoA  Coenzyme A 
CoaA  Pantothenate Kinase 
CTP  Cytidine triphosphate 
D  Aspartate 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E  Glutamate 
Ec  Escherichia coli 
EDTA  Ethylenediaminetetra-acetic acid 
FAS  Fatty acid synthase 
Glc  Glucose 
Glu  Glutamate 
GTP  Guanidine triphosphate 
HEPES  N-2-Hydroxyethylpiperazine-N’-2-ethane sulphonic acid 
Hp  Helicobacter pylori 
Hsp  Heat shock protein 
kcat  Turnover number 
kDa  Kilodalton 
KM  Michaelis constant 
LB  Luria Bertani 
MIC  Minimal inhibitory concentration 
N  Asparagine 
xiii 
NADH  Nicotinamide adenine dinucleotide (reduced) 
OD  Optical density 
PAGE  Polyacrylamide gel electrophoresis 
PanCOOH  Pantothenate 
PanK  Pantothenate kinase 
PCR  Polymerase chain reaction 
PEP  Phosphoenolpyruvate 
Sa  Staphylococcus aureus 
SDS  Sodium dodecyl sulphate 
spp.  Species (plural) 
TCA  Tri-carboxylic acid cycle 
TEMED  N,N,N’,N’,-tetramethyl-ethylene diamine 
Thr  Threonine 
TRIS  Tris(hydroxymethyl)aminomethane 
TRIS-HCl  Tris(hydroxymethyl)aminomethane-HCl 
UTP  Uridine triphosphate 
Vmax  Maximal velocity 
 
 
C h a p t e r  1  
A General Introduction 
Pantothenate is a member of the B group of vitamins and is an essential 
component of the acyl group carriers coenzyme A (CoA or CoA-SH) and acyl 
carrier protein (ACP).  These two acyl group carriers are present in all 
organisms and take part in more than 100 reactions in metabolism (1, 2). This 
study presents an overview of the biosynthesis of coenzyme A.  In particular it 
concentrates on pantothenate kinase, the enzyme catalysing the first reaction 
in the five-step biosynthesis of CoA. 
Chapter 2 concentrates on coenzyme A, giving an in depth review of its 
structure and function in metabolism.  It also looks at the biosynthesis of this 
cofactor in both prokaryotes and eukaryotes and the regulation of this 
pathway.   
Chapter 3 takes a closer look at the first reaction in the biosynthetic pathway 
to CoA, namely that catalyzed by pantothenate kinase (PanK).  This chapter 
gives a detailed account of the currently available literature on this enzyme.  
The analogues of PanK from various organisms are compared and the 
apparent absence of this enzyme function in certain pathogenic bacteria is 
noted. 
Following on from the information presented in chapter 3, chapter 4 reports 
our findings of a possible third analogue of pantothenate kinase.  We cloned 
and classified this analogue from B. subtilis and H. pylori.  Protein activity was 
tested by functional complementation and an independent kinetic assay for 
pantothenate kinase activity.  We make the suggestion that this is a third 
analogue of pantothenate kinase present in a subset of mainly pathogenic 
bacteria. 
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The protein classified in chapter 4 was assigned to a protein fold family based 
on information gleaned by protein structure prediction servers.  Alignments 
with proteins with the same folds whose structures have already been solved 
identify certain aspartate residues as conserved.  These conserved aspartate 
residues are suspected of playing a role in substrate and inhibitor binding.  
This hypothesis is tested by mutagenesis studies in chapter 5. 
Finally, chapter 6 summarizes the main findings of this study and highlights 
some interesting possibilities for future research with respect to this newly 
characterized pantothenate kinase enzyme.   
C h a p t e r  2  
Coenzyme A, Central to Metabolism 
2.1.  The Importance of Coenzyme A: 
Coenzyme A is a ubiquitous and essential cofactor in all living organisms.  It 
functions as an acyl group carrier and acyl activating group in a number of central 
metabolic transformations, including the tricarboxylic acid cycle and fatty acid 
metabolism.  Along with its thioesters, CoA is in demand as a substrate for 
approximately 9% of all enzyme activities, where it participates in a variety of acyl 
transfer reactions (2).  It has been estimated that CoA is involved in over 100 
different reactions in intermediary metabolism (1, 2).  CoA is the source of 4’-
phosphopantetheine, which is the prosthetic group of carrier proteins of fatty acid, 
polyketide and nonribosomal peptide synthases in mammals, bacteria and plants 
(2, 3).  CoA and its esters also function as regulators in several important reactions 
in intermediary metabolism such as pyruvate dehydrogenase and 
phosphoenolpyruvate carboxylase (4). 
As a result of CoA’s ubiquitous nature and its role as a cofactor in metabolism its 
levels must be stringently regulated.  In addition to this, the CoA biosynthetic 
pathway is an energetically expensive pathway (the production of one molecule of 
CoA uses three ATP equivalents), so it makes sense that the pathway itself be 
regulated as not to waste cellular energy.   
The biosynthetic pathway from pantothenate to CoA is essential in both prokaryotes 
and eukaryotes.  CoA is produced through a series of five enzymatic reactions from 
pantothenate or vitamin B5.  All the genes coding for the enzymes that catalyze the 
reactions in the biosynthetic pathway are known.  This chapter is a detailed account 
of coenzyme A’s structure, function and biosynthesis.  It also highlights this 
cofactors’ suitability as a drug target. 
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2.2.  Structure of CoA 
The German-born biochemist Fritz Lipmann discovered Coenzyme A in 1945 (5).  
He was the first to show that a coenzyme was required to facilitate biological 
acetylation reactions (the A in Coenzyme A stands for acetylation).  In 1953, 
Lipmann was awarded the Nobel Prize in physiology and medicine for his 
pioneering work in elucidating the role of this very important coenzyme.  CoA’s 
structure was first reported in 1953 (6).  Although CoA is a structurally complex 
molecule, it is functionally simple (Figure 2.1).   
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The structure of coenzyme A.  The coloured areas represent the different functional 
groups comprising the structure of CoA.  The area coloured in orange is 3’,5’-adenosine 
diphosphate (ADP); the area coloured in blue represents pantothenic acid; the green area represents 
β-mercaptoethylamine and the area in yellow highlights the reactive sulfhydryl group that forms 
thioester linkages with acyl groups. 
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CoA is made up of 3’,5’-adenosine diphosphate joined to 4’-phosphopantetheine in 
a phosphoric anhydride linkage.  The phosphopantetheine part of CoA consists of 
β-mercaptoethylamine and pantothenic acid, a member of the vitamin B family 
(vitamin B5).  The adenine moiety of CoA serves as the recognition site for enzyme 
to bind CoA.  This increases the affinity and specificity of CoA when it binds to the 
enzyme in question (5, 7).  The sulfhydryl group of the β-mercaptoethylamine 
moiety is the key functional group of the molecule as noted in the following section 
(8). 
2.3.  Function of Coenzyme A 
CoA has two main functions: 
• It activates acyl groups for transfer by nucleophilic acyl substitution 
• It activates the α-hydrogen of the acyl group for abstraction as a proton. 
These two functions are illustrated in Figure 2.2.   
 
 
 
 
 
 
Figure 2.2. The two general modes of reactivity of Acetyl-CoA.  The thioester carbonyl can act as 
an electrophile toward attack by a nucleophile cosubstrate.  The thioester α-carbon upon deprotonation 
can react as a nucleophile (5). 
It is pertinent to consider why acyl groups are carried in the form of thioesters rather 
than oxygen esters.  The most important consideration is the difference in 
resonance stabilization between these two functional groups.  
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Acidic protons (relative pKa = 21) 
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Figure 2.3. Resonance forms of the type that are important in the stabilization of esters do not 
contribute to the resonance stabilization of thiol esters. 
Sulphur is a third-row element with a limited ability to donate a pair of 3p electrons 
into the carbonyl π system.  With an electronegativity that is much less than 
oxygen, however, its destabilizing effect on the carbonyl group is slight, and 
thioesters lie in the middle of the group of carboxylic acid derivatives in respect to 
reactivity (9).  This translates to the fact that resonance forms of the type that are 
important in the stabilization of esters do not contribute to the resonance 
stabilization of thioesters (Figure 2.3). 
Carbanion formation at the α-carbon atom of the thioesters is more favourable than 
for oxygen esters.  Both of the carbanions are resonance stabilized in essentially 
the same way (Figure 2.4) (8).  However, because of the poor π-overlap between 
sulphur and the carbonyl group (as mentioned above) in the case of the thiol ester, 
its carbonyl group has more double bond character than that of the oxygen ester.  
Consequently, the resonance stabilization of the type shown here will be more 
favourable in stabilizing the α-carbanion of the thioester (8). 
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Figure 2.4. The carbanions of thiol esters and oxygen esters are resonance stabilized in 
essentially the same way, although carbanion formation at the alpha carbon of the thiol ester is 
more favourable. 
Acetyl-CoA is the most common CoA thioester.  Several enzymes are responsible 
for the formation of acetyl-CoA including acetyl-CoA synthetase, 
phosphotransacetylase, ATP citrate lyase and thiolase (5).  The enzymes that 
utilize acetyl-CoA can be divided into two main classes.  These are the Claisen 
enzymes, which catalyse reactions involving deprotonation of the α-carbon, and the 
acetyltransferases, which catalyse the nucleophilic acyl substitution reactions at the 
carbonyl carbon. 
2.3.1.  The Claisen Enzymes 
The Claisen enzymes utilize acetyl-CoA as a nucleophilic substrate via 
deprotonation of the methyl group.  The electrophile is the carbonyl group of an 
aldehyde, ketone, or thioester or the carboxy group of carboxybiotin.  Claisen 
enzymes are involved in a variety of biological pathways and the reactions 
catalysed by Claisen enzymes could occur through either a stepwise or concerted 
pathway (5). 
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2.3.2.  Acyltransferases 
Acyltransferases, as their name suggests, catalyse the transfer of the acyl group 
from a CoA thioester to a nucleophile acceptor, most commonly an alcohol or 
amine, or in the case of thioesterases, water.  Acyltransferases that specifically use 
acetyl-CoA are called acetyltransferases, which is the second major class of acetyl-
CoA utilizing enzymes (5). 
The biological significance of acetyltransferases is broad.  Bacterial acetylation of 
antibiotics renders the drugs inactive, thus conferring antibiotic resistance to many 
bacteria.  Acetylation also plays a key role in the transmission of nerve impulses 
(e.g. acetylcholine is a major neurotransmitter).  Acetylation of histones catalysed 
by histone-N-acetyltransferase is a vital control element in gene transcription, and 
several additional DNA-binding proteins may be acetylated as part of the 
transcriptional process (5). 
2.3.3.  Other CoA Ester-utilizing Enzymes 
Enzymatic reactions of longer chain CoA esters may involve functionality beyond 
the α-carbon.  Some examples of this are provided by the fatty acid β-oxidation 
cycle (Figure 2.5).  The reaction of acyl-CoA dehydrogenase results in oxidation of 
the α,β-unsaturated CoA ester.  Addition of water across the double bond catalysed 
by enoyl-CoA hydratase forms the β-hydroxy ester.  Fatty acid biosynthesis by fatty 
acid synthase is the approximate reversal of this β-oxidation cycle except that it is 
catalysed by a multi-enzyme complex.  Here the acetyl groups are not carried by 
acetyl-CoA but by acyl carrier protein (ACP) (5, 10).  The portion of ACP to which 
the acyl derivatives are bound as thiol esters is the 4’-phosphopantetheine moiety 
of CoA, thus acyl carrier protein (ACP) may be considered as chemically equivalent 
to CoA (8). 
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Figure 2.5.  The fatty acid β-oxidation cycle.  E1 = acyl-CoA dehydrogenase, E2 = crotonase, E3 = 
β-hydroxyacyl-CoA dehydrogenase, E4 = thiolase (5). 
Coenzyme A serves as a precursor to ACP via the transfer of its 4’-
phosphopantetheine moiety to apo-ACP (product of the acpP gene (11)) by the 
enzyme holo-ACP synthase (product of the acpS gene (12)).  In other words, holo-
acyl carrier protein is generated when apo-ACP is phosphopantotheinylated by the 
displacement of the adenine monophosphate moiety of coenzyme A by an active 
site serine in a reaction catalyzed by ACP synthase (1, 2, 5).   
ACP is a larger version of CoA, also using the phosphopantetheine group as a 
functional group for essentially the same purpose (Figure 2.6).  Intermediates in 
fatty acid synthesis are linked covalently to the sulfhydryl groups of ACP.  Fatty acid 
chains are constructed by the addition of two-carbon units derived from acetyl-CoA.  
The acetate units are activated by the formation of malonyl-CoA (at the expense of 
ATP).  The addition of two-carbon units to the growing chain is driven by 
decarboxylation of malonyl-CoA.   
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Figure 2.6.  Fatty acids are conjugated to both coenzyme A and acyl carrier protein through the 
sulfhydryl of the phosphopantetheine prosthetic group (7).   
 
The building blocks of fatty acid synthesis, namely acetyl and malonyl groups, are 
not transferred directly from coenzyme A to the growing fatty acid chain.  Rather 
they are first passed on to ACP and form acyl carrier protein conjugates.  ACP 
serves as the “transporter” of fatty acid biosynthesis intermediates.  The elongation 
reactions are repeated until the growing chain reaches 16 carbons in length 
(palmitic acid).  Other enzymes then add double bonds and additional carbon units 
to the chain.  In summary, ACP is used in fatty acid biosynthesis whereas CoA is 
used in β-oxidation of fatty acids, however, the formation of ACP is reliant the 
dephosphopantotheinoylation of coenzyme A (7). 
 
 
 
= phosphopantetheine group of CoA  
= phosphopantetheine prosthetic group of ACP 
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2.4.  Biosynthesis of CoA  
The biosynthesis of coenzyme A can be divided into two parts in bacteria.  First, 
pantothenate is synthesized, where after the universal biosynthesis of coenzyme A 
from pantothenate occurs.  The second part of the pathway is present in most 
organisms, even those that are not capable of de novo pantothenate synthesis.  
Unless stated to the contrary, the biosynthesis discussed below refers to E. coli. 
2.4.1.  Pantothenate in Nutrition 
Pantothenate is one of the B complex of vitamins (vitamin B5) (13).  During the 
1930’s a number of research programs were concentrating on growth factors for 
microrganisms and chick antidermatitis factor.  These studies resulted in the 
isolation, synthesis and characterization of the vitamin pantothenate.  Thereafter, 
pantothenate was found to play a fundamental role in all organisms (14).   
Animals and some microbes lack the capacity to synthesize pantothenate and are 
totally dependent on the uptake of pantothenate in their diets.  However, most 
bacteria, (2, 13, 15) plants and fungi are capable of synthesizing pantothenate (1).  
As a result of pantothenate being found virtually everywhere in biology it was 
designated pantothenate, which is derived from the Greek “pantothen” meaning 
“from everywhere” (1, 14).  It has been reported that E. coli, for example, produce 
and secrete 15 times more pantothenate than is required for intracellular CoA 
biosynthesis (16). This highlights the abundance of pantothenate available to 
organisms that harbour microorganisms.  It has been demonstrated that ruminants 
are capable of surviving without pantothenate supplementation from the 
pantothenate supplied to them by intestinal microorganisms (17).  As a result of 
pantothenate's ubiquitous nature a clinical deficiency of vitamin B5 has not been 
reported in humans (1, 14). 
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2.4.2.  The Pantothenate Biosynthetic Pathway in E. coli 
2.4.2.1.  A General Overview 
Bacteria synthesize pantothenate (Figure 2.6 and 2.7) from aspartate, α-
ketoisovalerate and ATP.  The biosynthesis begins with the decarboxylation of 
aspartate to give β-alanine.  Pantoic acid is formed by the hydroxymethylation of α-
ketoisovalerate followed by reduction of ketopantoate.  Pantoic acid and β-alanine 
are then condensed to generate pantothenic acid.  This section of the pathway 
occurs only in microbes and plants.   
Bacteria divert amino acids and intermediates from central metabolism to produce 
pantothenate.  Pantothenate is used in the biosynthesis of coenzyme A and the 
formation of ACP, the two predominant acyl group carriers in cells.  Most of what is 
known of the biosynthesis of pantothenate and coenzyme A has been learnt 
through research involving E. coli and Salmonella  typhimurium (13).   
2.4.2.2.  Biosynthesis in Detail 
α-Ketopantoate Biosynthesis 
The first step in the biosynthesis of D-pantoic acid is the transfer of a hydroxymethyl 
group from N5,10-methylenetetrahydrofolate to α-ketoisovalerate by α-ketopantoate 
hydroxymethyltransferase.  α-Ketopantoate hydroxymethyltransferase is the 
product of the panB gene (18).  The conversion of α-ketoisovalerate to pantoate 
proceeds stereospecifically, with inversion of the configuration at the C-3 carbon of 
α-ketoisovalerate (19).  It has been experimentally shown that the only pathway to 
pantothenate is from α-ketoisovalerate (20). 
Pantoate Biosynthesis 
D-Pantoate is synthesized from α-ketopantoate by α-ketopantoate reductase, which 
is the product of the panE gene (13).  It has been determined that acetohydroxy 
acid isomeroreductase (the ilvC gene product) is also capable of catalyzing the 
reduction of α-ketopantoate.  This means that mutants that do not contain the panE 
gene can still survive provided that the ilvC gene is expressed abundantly, 
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however, when this gene is not expressed at significant levels, the mutants do 
require pantoate for growth (21). 
β-Alanine Biosynthesis 
On the basis of a study of intact cells it was suggested that aspartate was the 
precursor of β-alanine (22, 23).  Two independent scientific groups, Williamson and 
Brown (24) and Cronan (25) characterized an L-aspartate-1-decarboxlase enzyme 
used in E. coli to convert aspartate to carbon dioxide and β-alanine.  The gene 
responsible for the expression of this enzyme is panD.  It has been shown that 
panD mutants require supplementation with β-alanine in order to grow (25, 26). 
 
 
Figure 2.6. A schematic illustration of the complete biosynthetic pathway of CoA in E. coli.  . 
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Figure 2.7.  The pantothenate biosynthetic pathway in E. coli 
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Pantothenate Biosynthesis 
Pantothenate synthetase is the enzyme responsible for the condensation of 
pantoate with β-alanine.  Pantothenate synthetase exists as a homotetramer (27-
29).  It has been established that pantothenate synthase is a product of the panC 
gene (30, 31).  Since the activity of pantothenate synthase is not tightly regulated, 
E. coli secretes most of the synthesised pantothenate into the medium in vivo (32-
34). The significance of this overproduction of pantothenate points to a role of 
intestinal flora in providing this vitamin to the mammalian host (32). 
2.4.3.  Pantothenate and Transport 
Plants and microbes synthesise pantothenate de novo as discussed above (35).  
Bacteria are capable of moving pantothenate across membranes bidirectionally.  
The best-characterized transport system exists in E. coli.  This is the high-affinity 
pantothenate permease, which catalyzes the concentrative uptake of pantothenate 
by a sodium ion cotransport mechanism (36, 37).  Pantothenate permease is a 
member of inner membrane permeases that catalyze active cation-dependent 
symport.  A similar transport system is present in S. typhimurium (38).  
Pantothenate permease is also called the PanF protein and is encoded by the panF 
gene (36). 
PanF is predicted to contain 12 transmembrane hydrophobic domains connected to 
each other by short hydrophilic chains.  This is a topological motif that is 
characteristic of other cation-dependent permeases of the major facilitator 
superfamily of proteins (16, 39).  This transport system is extremely specific for 
pantothenate, with a Kt of 0.4 µM and a maximum velocity of 1.6 pmol/min/108 cells 
(36, 37).  Overexpression of the PanF protein in E. coli produced a 10-fold increase 
in the amount of pantothenate incorporated into the cell as well as an increase in 
the steady state intracellular concentration of pantothenate (16).  However, the 
levels of coenzyme A biosynthesis remain unaffected.  This clearly indicates that 
CoA biosynthesis is not regulated by the amount of pantothenate available (16). 
In bacteria not capable of synthesizing pantothenate the pantothenate permease 
transport system is indispensable (16).  Pantothenate permease is only responsible 
Chapter 2:  Coenzyme A, Central to Metabolism       16 
 
for transporting pantothenate into the cells while another, still uncharacterized, 
transport system is responsible for expulsion of pantothenate from the cells.  This 
efflux system may play a role in the kinetic control of pantothenate phosphorylation 
by ensuring that the intracellular concentration of pantothenate remains low (13, 
40). 
2.4.4.  Coenzyme A Biosynthesis From Pantothenate. 
Unless stated to the contrary, the following section describes the biosynthetic 
pathway in E. coli (Figure 2.8). 
 
Figure 2.8. Biosynthesis of Coenzyme from pantothenate (1). CoaA, Pantothenate kinase (PanK); 
CoaB, Phosphopantothenoylcysteine synthetase; CoaC, Phosphopantothenoylcysteine 
decarboxylase; CoaD, Phosphopantetheine adenylyltransferase; CoaE, Dephospho-Coenzyme A 
kinase.  Numbers indicate the following: 1 pantothenate, 2 4’-phosphopantothenate, 3 4’-
phosphopantothenoylcysteine, 4 4’-phosphopantetheine, 5 dephospho-Coenzyme A, 6 Coenzyme A. 
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2.4.4.1.  Phosphorylation of Pantothenate  
Pantothenate kinase, also known as PanK or CoaA, catalyses the ATP-dependent 
phosphorylation of pantothenate to form phosphopantothenate.  This is the first 
committed step in the biosynthesis of coenzyme A, since none of the 
phosphorylated intermediates formed in the subsequent reactions can enter the 
cell.  Pantothenate kinase is encoded by the coaA gene. 
Because of CoA’s metabolic centrality, the enzyme(s) that regulates its production 
is of paramount importance.  This study concentrates on the pantothenate kinase 
enzyme, the most probable candidate to fill this role.  In particular, we are interested 
in the apparent absence of a pantothenate kinase analogue in some organisms. 
Chapter three focuses on PanK and discusses the enzyme in greater detail. 
2.4.4.2.  Formation of 4’-Phosphopantetheine 
Phosphorylation of pantothenate (1, numbers correspond to structures in Figure 2.8 
above) to form 4’-phosphopantothenate (2) is followed by condensation of 4’-
phosphopantothenate with cysteine, catalysed by an enzyme known as 4’-
phosphopantothenoylcysteine synthetase, (PPCS/CoaB, coaB gene product) 
producing 4’-phosphopantothenoylcysteine (3).  Thereafter, decarboxylation of 4’-
phosphopantothenoylcysteine by 4’-phosphopantothenoylcysteine decarboxylase 
(PPCDC/CoaC, coaC gene product) yields 4’-phosphopantetheine (4) (2). 
The activities of these two proteins are fused in most prokaryotes such as E. coli.  
The coaBC gene (originally dfp (41, 42)) encodes a flavin mononucleotide (FMN)-
containing bifunctional enzyme responsible for both the 4’-phosphopantothenoyl-
cysteine synthetase and the 4’-phosphopantothenoylcysteine decarboxylase 
activities (4, 43). 
The eukaryotic counterparts of these two enzymes are monofunctional and show 
very little sequence similarity to the bacterial proteins (44-46).  Neither 4’-
phosphopantethenolycysteine nor 4’-phosphopantothenate is detected in vivo (32) 
owing to the rapid conversion of both to 4’-phosphopantetheine. 
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2.4.4.3.  Conversion of 4’-phosphopantetheine to Coenzyme A 
There are two enzymatic steps involved in the conversion of 4’-phosphopantetheine 
to CoA (13).  Adenylation of 4’-phosphopantetheine by 4-phosphopantetheine 
adenyltransferase (CoaD, expressed by the coaD gene) and ATP yields 
dephospho-coenzyme A (5).  During this step the enzyme transfers the AMP moiety 
from ATP to 4’-phosphopantetheine with the release of PPi (13).  Phosphorylation 
of the 3’-hydroxyl of dephospho-coenzyme A by dephospho-coenzyme A kinase 
(CoaE, product of the coaE gene) completes the biosynthesis of coenzyme A (6).   
In mammals these two enzymes are copurified and exist as a bifunctional protein 
called CoA synthase.  
Metabolite labelling experiments1 have detected intracellular and extracellular 4’-
phosphopantetheine.  This suggests that 4’-phosphopantotheine adenyltransferase 
is a secondary control point in the biosynthesis of CoA (32, 47).  Experiments 
indicate that extracellular 4’-phosphopantetheine is derived from the degradation of 
ACP, and reutilization of this intermediate (before it is excreted) is regulated at the 
adenylyltransferase step (48).  Excretion of 4’-phosphopantetheine is an irreversible 
way to reduce the intracellular CoA and ACP content as E. coli is incapable of 
assimilating CoA from exogenous 4’-phosphopantetheine (48). 
                                                 
1 The concept of metabolite labelling refers to stable isotope labelling of an intracellular chemical 
precursor or metabolite and allows the direct detection of downstream metabolites of that precursor, 
arising from novel enzymatic activity of interest, using metabolite profiling liquid chromatography-
mass spectrometry (LC-MS).  This approach allows the discrimination between labelled downstream 
metabolites produced from novel enzymatic activity from the unlabeled forms of the metabolite 
arising from native enzyme activity.   
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2.5.  Regulation of Coenzyme A Levels. 
Coenzyme A and its thioester derivatives are important cofactors participating in 
over 100 different reactions in intermediary metabolism of microorganisms.  
Moreover, they regulate several key metabolic reactions (49).  This being the case, 
their production must be tightly controlled to prevent metabolic activity running 
awry.  CoA levels can be regulated in one of five ways: 
• The compartmentalization of CoA 
• Feedback regulation by pantothenate kinase 
• Secondary regulation by 4’-phosphopantetheine adenyltransferase 
• Regulation of CoA levels by gene expression 
• Regulation by degradation 
The next section describes the above means of regulation in little more detail. 
2.5.1.  Compartmentalization of CoA 
Sequestered pools of CoA exist in eukaryotic cells.  These are essential for 
activating carboxylic acid metabolites.  Intracellular CoA levels are limited by the 
membranes surrounding the mitochondria and peroxisomes.  In mammals, 
mitochondrial CoA is used as a cofactor in the Krebs cycle and fatty acid β-
oxidation, thus the concentration of free CoA and its thioesters regulate the rates of 
these processes (50).  CoA also donates the 4’-phosphopantetheine prosthetic 
group to activate mitochondrial ACP that is involved in mitochondrial fatty acid 
synthesis (51-55).  Peroxisomes are involved in the β-oxidation of very long-chain 
fatty acids and therefore have high concentrations of CoA (56, 57).   
2.5.2.  Feedback Regulation by Pantothenate Kinase 
Pantothenate is not a rate limiting intermediate because bacteria produce 15 times 
more pantothenate than is required for CoA biosynthesis.  In addition to this, 
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overexpression of pantothenate permease (responsible for transport of 
pantothenate into the cell) does not increase the production of coenzyme A in the 
cell (16).  Pantothenate kinase is the key regulatory point in the control of CoA 
levels in the cell.  It is subject to feedback inhibition by CoA itself and to a lesser 
extent by CoA thioesters (58, 59).  This is evidenced by the work done by Song and 
Jackowski who discovered that a 76-fold overexpression of pantothenate kinase 
only resulted in a 2.7 fold increase in the cellular concentration of CoA (60).  This 
feedback inhibition of PanK by the different CoA molecular species controls the 
overall CoA availability in response to the cell’s metabolic status.  In E. coli, the 
CoA pool consists mainly of acetyl-CoA, followed by nonesterified CoA, succinyl-
CoA and malonyl-CoA.  The total amount of CoA and the variety distributed through 
the cell is dependent on the carbon source in which the E. coli bacteria are cultured 
(61). 
The crystal structure of E. coli PanK in complex with either ATP or CoA has been 
determined (62).  Based on this structural data, Rock et al. (63) set about designing 
three site-directed mutants of PanK that were predicted to be resistant to feedback 
inhibition by CoA based on decreased binding efficiencies of this inhibitor.  These 
mutants CoaA(R106A), CoaA(H177Q), and CoaA(F247V) were shown to retain 
significant activity and be refractory to inhibition by CoA.  CoaA[R106A] retained 
50% activity while the other two mutants were less active.  The presence of Arg 106 
is postulated to be an important and specific requirement for CoA binding since it 
forms a salt bridge with the phosphate attached to the 3’-hydroxyl of the CoA 
ribose.  The authors state that this residue does not have a role in catalysis.  The 
authors show that the mutants that are refractory to feedback inhibition accumulate 
intracellular phosphorylated pantothenate-derived metabolites, thus translating into 
a higher CoA content (63).  This data confirms that the feedback inhibition is 
operating in vivo to limit the amount of CoA being produced. 
The feedback inhibition of the PanK enzyme by CoA is competitive with ATP 
binding at the active site (58, 61, 62).  Thus CoA biosynthetic activity can be 
modulated depending on the energy state of the cell.  This means that a reduction 
in the ATP level would allow for more binding of the feedback inhibitor and a 
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reduction in the rate of CoA biosynthesis (1).  In this way, the levels of CoA are 
collectively controlled by the amount of the predominant CoA species and the ATP 
levels in the cell (61). 
The eukaryotic PanK enzymes are also feedback regulated by CoA and CoA 
thioesters.  Acetyl-CoA and palmitoyl-CoA selectively and strongly inhibit the 
Aspergillus nidulans PanK in a competitive way with ATP (64).  Human PanK2 
protein is very sensitive to long-chain acyl-CoA, acetyl-CoA and malonyl-CoA, 
whereas nonesterified CoA is a much less effective inhibitor (65). 
Pantothenate kinase is the subject of chapter 3, where the different analogues of 
PanK are discussed and compared in detail. 
2.5.3.  Secondary Regulation by CoaD 
Experiments using metabolite labelling have detected intracellular and extracellular 
4’-phosphopantetheine, suggesting that 4’-phosphopantotheine adenyltransferase 
(CoaD) is a secondary control point in the biosynthesis of CoA (32, 47, 66).  While 
the primary means of regulation is through PanK, regulation by CoaD becomes 
more important when the regulation at the PanK site is disrupted (63) or when the 
PanK protein is overexpressed (60).  In both instances the amount of intracellular 
and extracellular 4’-phosphopantetheine increases and this reflects restriction of the 
flux through the coenzyme A biosynthetic pathway by CoaD.  4’-
phosphopantetheine cannot be transported back into the cells (66).  It is predicted 
that the CoaD protein is feedback regulated by free CoA, much like PanK (32, 47, 
63, 67).  This hypothesis is based on the time- and concentration-dependent 
correlation between accumulation of intracellular CoA and the exit of 4’-
phosphopantetheine from the cells (32, 47).  This is supported by biochemical 
studies of the CoaD protein.  When CoaD is purified from E. coli, CoA remains 
bound to the CoaD protein in a ratio of 1 mole per 2 moles of protein (68).  In 
addition to this, the crystal structure of CoaD bound to CoA indicates that the CoA 
binds to the 4’-phosphopantetheine site (67).  S. aureus does not show the same 
inhibition by CoA of the homologous CoaD protein (1, 69).  In mammalian cells the 
pool of 4’-phosphopantetheine is almost as high as that of pantothenate and when 
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PanK1 is overexpressed, the 4’-phosphopantetheine pool increases almost 3-fold 
(1). 
2.5.4.  Regulation of CoA Levels by Gene Expression 
CoA biosynthesis is regulated enzymatically by negative feedback of PanK.  
However, the upper threshold of the intracellular CoA concentration is set by the 
levels of coaA gene expression in E. coli and most bacteria.  The coaA promoter 
has poor sequence homology with the consensus E. coli promoter sequences.  In 
addition to this, the coaA coding region contains a relatively large percentage of low 
usage codons (60).  This means that in relation to the average E. coli protein, PanK 
protein levels are low.  When the coaA is amplified in a multi-copy plasmid in E. coli 
a 76-fold higher enzyme activity and a 3-fold increase in the steady state levels of 
CoA is the result (60).  However, feedback inhibition of the PanK enzyme prevents 
the concentration of CoA rising unchecked.  No evidence has been found for the 
regulation of the coaA gene on a transcriptional level and it seems that bacteria 
control the CoA levels sufficiently on a biochemical level (1). 
In contrast, mammalian cells and tissues modulate PanK expression to modify CoA 
levels in long-term response to diet and disease.  The mechanism by which this 
occurs is, however, still unknown (1). 
2.5.5.  Regulation by Degradation 
CoA levels can also be regulated by degradation of the coenzyme.  CoA can be 
dephosphorylated to dephospho-CoA or hydrolyzed by cleavage of the 
phosphodiester bond yielding 4’-phosphopantetheine.  As an alternative to direct 
CoA degradation, the 4’-phosphopantetheine moiety of CoA can be transferred to 
carrier proteins like the acyl carrier protein (ACP) of bacteria or the fatty acid 
synthase (FAS) in eukaryotes.  This 4’-phosphopantetheine is the prosthetic group 
that activates these proteins and allows them to form thioester linkages with 
carboxylic acids (1). 
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2.6.  Coenzyme A as a Drug Target 
Research involving CoA has always been popular due to its biochemical centrality; 
however, a discovery in 1999 heightened this interest.  The cloning of the first 
eukaryotic pantothenate kinase from fungus revealed a sequence completely 
different to that of E. coli PanK (64).  However, this protein from Aspergillus 
nidulans is homologous to several proteins encoded by mammalian genes (70-73).  
This discovery (that the bacterial PanK was different to mammalian PanK) led to the 
prediction that the pantothenate kinase step was a prime target for the identification 
and design of novel antibacterial drugs.   
The development of new antibiotics designed as inhibitors of CoA utilizing enzymes 
(such as CoA antivitamins or antimetabolites) would be very beneficial.  In this 
context, antivitamins and antimetabolites are analogues of pantothenate that will be 
incorporated into the CoA biosynthetic pathway producing CoA analogues that are 
inactive.  Even though many CoA analogues have been designed as CoA utilizing 
inhibitors in vitro they have not been useful as antibiotics because bacteria are 
unable to transport CoA across the cell membrane. 
The significance of extensive research focussing on CoA cannot be overstated.  
This subject is extended in the following chapter highlighting the relevance of 
pantothenate kinase’s role in the regulation of CoA. 
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 C h a p t e r  3  
Pantothenate Kinase, an Overview 
3.1.  Introduction 
From chapter 1, it is clear that coenzyme A plays a central role in metabolism.  As a 
result of this, enzymes involved in this cofactors’ biosynthesis are also important as 
research candidates.  We are interested in one enzyme in particular, pantothenate 
kinase (ATP:D-pantothenate 4’-phosphotransferase).  Pantothenate kinase 
catalyses the first committed step in the Coenzyme A biosynthetic pathway.  It 
catalyzes the transfer of the terminal phosphate from ATP to pantothenate, forming 
phosphopantothenate. 
This chapter focuses on coenzyme A biosynthesis and concentrates on 
pantothenate kinase in particular, giving an overview of the different analogues2 of 
this enzyme and how they differ from one another in terms of inhibition, sequence 
and structure.   
Currently two analogues of the enzyme have been characterized: the first (Type I) 
is found predominantly in prokaryotic organisms and is exemplified by the 
Escherichia coli PanK enzyme (2).  The second (Type II) occurs mainly in 
eukaryotic systems, of which the murine enzyme (MmPanK1β) has been the best 
characterized (3). 
                                                 
2 In this study we refer to analogues as genes or proteins that display the same activity but lack 
sufficient similarity to imply common origin.  The implication is that analogous proteins followed 
evolutionary pathways from different origins to converge upon the same activity.  Thus, analogous 
genes or proteins are considered a product of convergent evolution (1).  In contrast, a protein 
isoform is a version of the same protein with some small differences, usually a splice variant or the 
product of some posttranslational modification, and normally refers to the same protein occurring in 
different locations in the cell   Due to these differences, we shall refer to the different PanK proteins 
in this study as analogues. 
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Recent studies have indicated that this classification is not unambiguous, as the 
Staphylococcus aureus PanK has a primary structure that is more closely related to 
Type II pantothenate kinases than to the Type I PanK’s.  In addition to this, it is not 
regulated by feedback inhibition by CoA or its thioesters (4). 
The Type I and II analogues show very little sequence homology and are predicted 
to be structurally distinct.  Despite this, they share a common regulation mechanism 
based on feedback inhibition by CoA and its thioesters, although the degree of 
inhibition is system- and inhibitor-dependent (3, 5-10).  This feedback mechanism is 
primarily responsible for controlling the intracellular CoA concentration (5, 7, 10).   
Because of the lack of sequence homology between the two analogues, it has been 
predicted that they adopt different three-dimensional structures.  This chapter 
serves as an overview of the currently available information pertaining to the 
pantothenate kinase enzymes classified thus far and intimates the likelihood of two 
additional, unclassified analogues of this enzyme. 
3.2.  Type I Pantothenate Kinase 
The pantothenate kinase enzyme was first identified in S. typhimurium (11) and E. 
coli (12) and thereafter in numerous other bacteria by comparative genomics (13, 
14).  The PanK protein from E. coli (13) has been expressed and purified.  This 
prokaryotic pantothenate kinase enzyme is what we refer to as the Type I 
pantothenate kinase.  In this study, the pantothenate kinase enzyme from 
Escherichia coli will represent the Type I PanK and when Type I is mentioned, the 
E. coli analogue is implied. 
3.2.1.  E. coli Pantothenate Kinase, the Prototypical Bacterial PanK 
The PanK from E. coli is structurally distinct from its eukaryotic counterparts (8, 13, 
14).  The E. coli enzyme has been extensively studied and characterized, in fact, it 
is considered the prototypical bacterial PanK.  E. coli is capable of de novo 
pantothenate biosynthesis, but can also actively transport exogenous pantothenate 
into the cell through a sodium-dependent permease (PanF) (15-17).  Metabolic 
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labelling experiments have established that it is the utilization of pantothenate 
rather than the supply of pantothenate that controls the rate of CoA biosynthesis 
(18).  Temperature sensitive E. coli PanK mutants have a growth phenotype that 
causes a temperature-dependent inactivation of pantothenate kinase activity at 
temperatures higher than 42˚C (12).  The pantothenate kinase gene of E. coli 
(coaA) was cloned by functional complementation of the temperature sensitive 
mutant and (12) and was found to be identical to a previously sequenced allele 
called rts (19, 20).  The E. coli coaA transcript has two translation initiation sites and 
the PanK protein was first identified as a mixture of two peptides.  The shorter 
protein lacks the first eight N-terminal amino acid residues (20). 
There is a single nucleotide-binding site on each monomer.  The binding of ATP to 
the homodimer is highly cooperative and mediates sequential ordered catalysis with 
ATP as the leading substrate (9).  CoA and its thioesters inhibit bacterial PanK 
activity by binding competitively to the ATP binding site (9, 10).  Nonesterified CoA 
is the most potent inhibitor of bacterial PanK in vitro and in vivo, whereas acetyl-
CoA is about 20% as effective as CoA (10).  It is postulated that the additional acyl 
chain in acetyl-CoA (steric hindrance) is the reason that it is a less potent inhibitor 
than CoA, which fits snugly into the pantothenate binding pocket (10).  The crystal 
structure of PanK in complex with ATP or CoA has been determined (Figure 3.1) 
(6).  These structures revealed that ATP and CoA bind to the enzyme in different 
ways.  Despite this their phosphate binding sites overlap at Lys 101.  This explains 
the competition between the CoA regulator and the ATP substrate (21).  This 
negative feedback mechanism of inhibition is the primary manner in which bacteria 
control the cellular level of CoA.   
A survey conducted by Cheek et al (22) has characterized all known kinases into 
specific groups and families based on their three dimensional structure.  Based on 
the crystal structure of the Type I PanK the authors place this analogue into the 
Rossmann-like fold group (group 2).  Within this group they are classified into the P-
loop kinase family.  The P-loop family constitutes the largest family in the 
Rossmann-like fold group (22).  
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Figure 3.1. Close-up stereoview of the overlapping site of two ligands, AMPPNP and CoA. The 
binding pockets of AMPPNP and CoA are shown in yellow and cyan, respectively. CoA (magenta) and 
AMPPNP (black) are shown in lines. a, residues of the AMPPNP-bound enzyme are shown in brown, 
and residues of the CoA-bound enzyme are not shown for clarity. Note that the carboxyl group of 
Glu249 of the AMPPNP-bound enzyme coincides with the pantetheine moiety of CoA. b, residues of 
the CoA-bound enzyme are shown in green, and residues of the AMPPNP-bound enzyme are not 
shown for clarity. Note that the carboxyl group of Glu44 of the CoA-bound enzyme coincides with the 
adenine base of AMPPNP (6).  Figure reproduced with permission from Yun et al. (2000). J. Biol. 
Chem. 275, 28093-28099. 
Although the E. coli PanK is considered the model bacterial pantothenate kinase, 
this analogue is not universally expressed in bacteria (23).  For example, the 
eubacteria Pseudomonas aeruginosa and Helicobacter pylori do not have 
recognizable pantothenate kinases in their genomes, although all other components 
of the biosynthetic pathway are present. 
Chapter 3:  Pantothenate Kinase, an Overview  35 
 
3.3.  Type II Pantothenate Kinase 
Mammalian pantothenate kinase belongs to the group of Type II pantothenate 
kinases.  Of the mammalian pantothenate kinases, perhaps the best characterized 
is the murine pantothenate kinase.  The murine pantothenate kinase (PanK1) gene 
consists of seven introns and eight extrons and is located on chromosome 19.  Two 
biochemically distinct PanK1 isoforms, namely, PanK1α and PanK1β, are encoded 
by this PanK1 gene.  The two isoforms differ with regards to their regulatory 
properties.  The PanK1α isoform is inhibited by free and long-chain acyl-CoA and 
more distinctly inhibited by acetyl-CoA and malanoyl-CoA in comparison to the 
PanK1β isoform.  This infers distinct regulatory properties by the α and β isoforms, 
in fact, the PanK1β isoform is only weakly inhibited by acetyl-CoA and stimulated 
by CoA.  The isoforms are differentially expressed in mouse tissue as a result of the 
metabolic status of the tissue (3, 7).  Cells modulate PanK expression to modify 
tissue CoA levels in response to diet and disease.  The mechanism in which they 
do this is largely unknown.  However, it is clear that the metabolic state of the 
animal (24-28), pathological condition such as diabetes (29, 30), and hypolipidemic 
drugs (27, 31, 32) all significantly effect the cellular levels of coenzyme A. 
The Aspergillus nidulans PanK, also characterized as a Type II PanK, is sensitive to 
inhibition by acetyl-CoA but not effected, positively or negatively, by CoA.  This 
indicates that the properties of the fungal enzyme are intermediate between the 
mPanK1α and mPanK1β.  It is clear that the characteristics of the eukaryotic (Type 
II) pantothenate kinases are in sharp contrast to the prokaryotic (Type I) PanK in 
terms of inhibition, with Type I PanKs being inhibited predominantly by CoA and to 
a lesser extent acetyl-CoA, and the Type II PanK’s being inhibited more potently by 
acetyl-CoA (9). 
Unlike the Type I pantothenate kinases, which belong to the P-loop family of 
kinases, the Type II PanK’s are predicted to belong to the ribonuclease H-like 
kinase group.  The ribonuclease H-like group contains the ASKHA (acetate and 
sugar kinase/hsc70/actin) superfamily (33). 
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3.3.1.  Pantothenate from Staphylococcus aureus, an Atypical 
Type II PanK 
Even though S. aureus is a bacterium, its PanK primary sequence is distinctly 
different from that of E. coli.  In fact, it is more closely related to mammalian 
pantothenate kinases than to those of its fellow bacteria (4).  S. aureus’ PanK 
primary sequence (8, 14, 34) shares 18% identity with the murine PanK isoform 1β 
(MmPanK1β) and only 13 % identity with E. coli PanK.   
The native molecular mass of S aureus PanK is 59 kDa, which is consistent with 
the existence of a homodimer (4).  All organisms characterized to date share a 
common mechanism to regulate CoA biosynthesis, feedback inhibition by CoA 
and/or its thioesters.  The key difference between S. aureus PanK and other 
pantothenate kinases is that it is refractory to feedback inhibition by CoA and its 
thioesters (3, 7, 8, 10).  S. aureus produces CoA in proportion to the input of β-
alanine with no indication of regulation at PanK or in downstream reactions.  This 
observation may be understood in the light of the physiology of S. aureus.  
Prokaryotes and many eukaryotes use glutathione as the major low-molecular 
weight thiol, which, together with an NADPH-dependent glutathione reductase, 
constitutes the primary thiol/disulphide redox system (35, 36).  This system is 
essential for maintaining the intracellular reducing environment and protects the 
organism from oxidative assaults by functioning in the detoxification of peroxides, 
epoxides and other products of reactive oxygen (4).  S. aureus does not contain 
glutathione (37).  In S. aureus, CoA is the primary intracellular thiol and together 
with a unique CoA disulphide reductase functions as the reducing system (38, 39).  
Because of this the concentration of CoA in S. aureus can reach millimolar levels 
(38, 39), and the lack of CoA feedback regulation in this organism means that the 
upper limit of CoA is set by the availability of the starting materials of CoA 
biosynthesis, namely pantothenate and cysteine.  As a result CoA levels are limited 
by the supply of pantothenate produced by the biosynthetic pathway encoded for by 
the panBCDE genes (40). 
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3.4.  Type III Pantothenate Kinases 
As discussed, at least two analogues of PanK exist in nature.  These analogues 
show very little sequence homology and are predicted to be structurally distinct.  
However, sequence analysis of bacterial genomes, using these two analogues as 
templates, fails to locate a homologue of either analogue in some species.  Since 
PanK activity is required for the biosynthesis of CoA in all living systems such a 
gene must exist in these species.  The group of species lacking analogues of the 
currently identified pantothenate kinases can be separated into two subgroups:  
those belonging to the family of archeabacteria, and those that include well-known 
pathogenic eubacteria such as Bordetella spp., Helicobacter pylori and 
Pseudomonas spp.  Since these organisms possess sequences that are 
homologous to all the other CoA biosynthetic genes, it is highly likely that at least 
one other analogue of PanK exists that represents this activity in these bacteria.  
This analogue would have little or no sequence homology to the well-characterised 
analogues (14). 
A recent patent application has claimed to have identified a gene sequence which, 
when cloned in trans, can suppress the effects of an E. coli PanK temperature 
sensitive mutant (41).  This sequence was identified from the genome of Bacillus 
subtilis.  This organism does already possess a gene homologous to the Type I 
pantothenate kinase.  In support of the suggested duplication of PanK activity, 
interruption of the putative B. subtilis coaA gene gave a normal-growing phenotype.  
However, experiments aimed at the additional deletion of the identified gene 
sequence failed.  This indicates that the simultaneous deletion of both genes is 
lethal to B. subtilis.  This strongly supports that the identified gene, dubbed coaX, 
encodes a protein that exhibits pantothenate kinase activity.  Homology searches 
based on the coaX gene sequence identified orthologues in several bacterial 
genomes, including those eubacteria that do not possess another PanK analogue.  
Included among these are various pathogenic bacteria like Bordetella pertussis (the 
causative agent for whooping cough) and the category A biodefence pathogen, 
Francisella tularensis.  Some organisms, such as B. subtilis, contain a gene 
sequence homologous to both coaA (Prokaryotic, Type I) and coaX.  This indicates 
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that the putative duplication of PanK activity is not unique (42).  The results of these 
searches are summarized in Table 3.1. 
Interestingly, the coaX homologue in B. pertussis has been studied before and was 
found to be an essential gene in this organism (43, 44).  However, these studies 
concluded that the gene product was involved in pertussis toxin production via 
interaction with the two-component transcriptional regulator BvgAS.   
Bordetella pertussis is a coccobacillus that causes the upper respiratory tract 
disease pertussis (whooping cough) in humans (44).  B. pertussis produces multiple 
attachment factors and toxins that together produce the symptoms of the disease.  
The attachment factor and toxin production are innitiated by the products of the 
bvgAS locus, namely BvgA and BvgS.  BvgS is a transmembrane sensor protein 
that in response to the absence of environmental stimuli (MgSO4, nicotinic acid, or 
growth at low temperatures) activates BvgA.  BvgA is a cytoplasmic protein which, 
when activated by BvgS, binds upstream to virulence genes and positively 
influences their transcription.  BvgS activates BvgA by phosphorylation.  Two of 
these virulence genes are termed ptx and cya, and they require an accessory factor 
in order for BvgA to activate their transcription.  This accessory protein was cloned 
and expressed and termed Bvg accessory protein (Baf) (44).   
Baf does not have any significant sequence homology to any of the known bacterial 
transcriptional regulators.  What is unusual is that it shows homology (28% identity 
and 49% similarity) to CoaX from B. subtilis.  The results presented by DeShazer et 
al. suggest that a Baf mutation may be lethal (43, 44).  Thus, Baf may regulate the 
expression of some essential B. pertussis genes, or it may be essential itself.   
Bordetella falls into the group of eubacteria that do not have a gene sequence 
homologous to either the known PanK analogues.  The Baf protein, however, is 
homologous to CoaX, the protein with putative PanK activity.  Although the 
transactivation experiments that lead to its annotation are completely unrelated to 
CoA biosynthesis, the same study did aim to create a Baf deletion mutant in 
Bordetella, but failed (43).  This indicates that Baf is essential in B. pertussis, 
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supporting its suggested role in CoA biosynthesis rather than implicating its 
involvement in a non-vital cellular process.  
Table 3.1.  Sequence homology analysis of bacterial genomes to confirm the presence of 
putative CoA biosynthetic enzymes 
Genome taxon
2.7.1.33  
CoaA 
(PanK)
 6.3.2.5 
CoaB
4.1.1.36  
CoaC 
2.7.7.3  
CoaD 
2.7.1.24  
CoaE
CoaX-
like 
PanK
1 Methanobacterium thermoautotrophicum A + + +
2 Methanococcus jannaschii A + + +
3 Methanopyrus kandleri AV19 A + + +
4 Thermoplasma acidophilum A + + +
5 Agrobacterium tumefaciens C58 B + + + + +
6 Bacillus anthracis A2012 B + + + + + +
7 Bacillus cereus ATCC 14579 B + + + + + +
8 Bacillus subtilis 168 B + + + + + +
9 Bacillus thuringiensis israelensis ATCC-35646 B + + + + + +
10 Corynebacterium glutamicum ATCC-13032 B + + + + +
11 Enterococcus faecalis B + + + + +
12 Escherichia coli K12 MG1655 B + + + + +
13 Haemophilus influenzae KW20 B + + + + +
14 Lactococcus lactis str. IL 1403 B + + + + +
15 Leuconostoc mesenteroides ATCC-8293 B + + + + +
16 Mycobacterium tuberculosis H37Rv B + + + + + +
17 Rhodobacter capsulatus B + + + + + +
18 Salmonella typhimurium LT2 B + + + + +
19 Staphylococcus aureus ATCC-29213 B + + + + +
20 Staphylococcus epidermidis ATCC 12228 B + + + + +
21 Streptococcus pneumoniae 23F B + + + +
22 Streptomyces coelicolor A3(2) B + + + + +
23 Vibrio cholerae El Tor N16961 B + + + + +
24 Yersinia enterocolitica 8081 B + + + + +
25 Yersinia pestis CO92 B + + + + +
26 Acinetobacter calcoaceticus ADP1 B + + + + +
27 Azotobacter vinelandii AvOP B + + + +
28 Bacillus stearothermophilus 10 B + + + + +
29 Bordetella pertussis B + + + + +
30 Borrelia burgdorferi B31 B + + + +
31 Burkholderia cepacia J2315 B + + + +
32 Campylobacter jejuni NCTC-11168 B + + + + +
33 Caulobacter crescentus CB15 B + + + + +
34 Clostridium botulinum ATCC-3502 B + + + + +
35 Cytophaga hutchinsonii ATCC-33406 B + + + +
36 Deinococcus radiodurans R1 B + + + + +
37 Haemophilus influenzae 86028NP B + + + +
38 Helicobacter pylori 26695 B + + + + +
39 Neisseria gonorrhoeae FA 1090 B + + + + +
40 Neisseria meningitidis ser. A strain Z2491 B + + + + +
41 Porphyromonas gingivalis B + + + + +
42 Pseudomonas aeruginosa PAO1 B + + + + +
43 Pseudomonas fluorescens Pf0-1 B + + + +
44 Pseudomonas putida KT2440 B + + + +
45 Ralstonia eutropha CH34 (JGI) B + + + + +
46 Synechocystis sp. PCC6803 B + + + +
47 Thermotoga maritima MSB8 B + + + + +
48 Xanthomonas campestris ATCC-33913 B + + + +
"UNIVERSAL PATHWAY, 5 steps
 
Note: Taxon refers to archaea (A) or eubacteria (B) 
Chapter 3:  Pantothenate Kinase, an Overview  40 
 
3.5.  Type IV PanK in Archaeabacteria 
Ulrich Genschel has recently conducted a study (13) where he attempted to 
systematically elucidate the evolutionary relationships of the CoA biosynthetic 
genes among bacteria, archaea, and eukaryotes.  He discovered that based on the 
phylogenetic distribution and the evolutionary histories of the CoA biosynthetic 
genes, two phases can be distinguished in the evolution of the pathway: CoA 
biosynthesis from phosphopantothenate was complete in the universal ancestor, 
while pathways for the synthesis of phosphopantothenate arose only after the 
separation of bacteria and archaea (13).  Genschel found that the conserved genes 
encoding for PanK (Type I and Type II) are generally lacking in archaea.  He 
investigated the possibility that the archaeal genomes may contain a more distantly 
related homologue to these enzymes by using iterative Psi-Blast searches against 
the archaeal subset of the NCBI peptide sequence database. 
The presence of conserved CoA biosynthetic genes indicates that several non-
methanogenic archaea produce pantoate in the same way as bacteria and that all 
archaea convert 4’-phosphopantothenate into CoA by using CoaB, CoaC, CoaD 
and CoaE activities.  Thus, at least one subset of archaeal species should be able 
to convert pantoate into phosphopantothenate.  However, no candidate genes were 
found by homology searches to PanC or PanK that could perform these enzyme 
functions (13).  This simplest explanation for this finding is that unrelated genes 
encode for PanC and PanK activities in archaea.  This possibility was explored by 
inferring functional links to archaeal genes for PanB, PanE, and CoaB/CoaC using 
the functional proximity method (refer Genschel 2004 (47)).  The results gained by 
these experiments indicate that COG1701 (uncharacterized protein that is 
conserved in archaea) and COG1289 (a predicted archaeal kinase) are very likely 
to represent archaeal forms of PanC and PanK, respectively.  The author states 
that this confirms that the set of enzymes for the synthesis of phosphopantothenate 
in methanogens is unrelated to the corresponding bacterial enzymes.  
Thermoplasma lack bacterial or archaeal enzymes for the synthesis of 
pantothenate and may be dependent on exogenous pantothenate.  All the archaea 
considered in Genschel’s study contained bifunctional CoaB/CoaC, CoaD, and 
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CoaE enzymes for the conversion of phosphopantothenate to CoA.  This means 
that in several non-methanogenic archaea, the topology of the synthesis of CoA 
from α-ketoisovalerate is conserved with that in bacteria and eukaryotes. 
To summarize, from comparative genomic analysis of the genes coding for PanK it 
is clear that no homologous gene coding for this enzyme has been discovered in 
the archaeabacteria (13).  The archaeabacteria have all the other genes that code 
for the remaining four steps in the universal biosynthesis of CoA (13, 23).  The 
PanK analogue in archaeabacteria is thus distinct from the Type I and II PanK 
analogues classified thus far.  In addition, it is distinct from the Type III PanK 
present in the predominantly pathogenic bacteria (Table 3.1).  This points to the 
existence of yet another analogue of pantothenate kinase.  This, together with the 
fact that CoA is essential indicates that there is a Type IV analogue in the 
archaeabacteria that has not yet been identified and characterized (13).   
3.6.  Pantothenate Antimetabolites 
In the context of the heading above, an antimetabolite is an alternative substrate for 
PanK that is phosphorylated and incorporated into the CoA biosynthetic pathway 
resulting in an analogue of coenzyme A.  The resulting CoA analogue may then act 
as an inhibitor of CoA and acetyl-CoA utilizing enzymes (45). 
The pantothenamides are such antimetabolites and are competitive with respect to 
pantothenate.  N-Pentylpantothenamide (N5-Pan) and N-heptylpantothenamide 
(N7-Pan) are effective inhibitors of bacterial cell growth (21).  The PanK-ADP-
pantothenate ternary complex structure in E. coli can explain how the bulky 
pantothenamide antimetabolites (Figure 3.2) are capable of being phosphorylated 
by pantothenate kinase.   
Their inhibitory action is thought to be due to pantothenate kinase converting them 
to their phosphorylated intermediates that are then incorporated into the CoA 
biosynthetic pathway.  The end result is the biosynthesis of CoA analogues that are 
inactive.  N5-Pan is metabolised through the CoA biosynthetic pathway to the 
cofactor analog ethyldethia-CoA (45).   
Chapter 3:  Pantothenate Kinase, an Overview  42 
 
Figure 3.2.  Structure of pantothenate compared to the pantothenamide antimetabolites.  
Pantothenate is the substrate for the reaction catalyzed by PanK, however, PanK phosphorylates both 
N5-Pan and N7-Pan with similar efficiency. 
The incorporation of these analogs into ACP, where they block fatty acid synthesis 
by the accumulation of inactive ACP, has been demonstrated.  This is the main 
cause for growth inhibition of E. coli when these pantothenamides are used as 
substrates (46).  This, coupled with the fact that the affinity of PanK for these 
antimetabolites is comparable to its affinity for pantothenate, is unusual because 
enzymes that utilise small molecules are usually highly selective for their substrates 
(21).  The flexibility of the pantothenate kinase binding site may account for its 
ability to phosphorylate the pantothenamides (21).   
Based on the interaction of ligands with the pantothenate-binding pocket in E. coli, 
the pantothenate-binding site is also part of the binding site for CoA (Figure 3.3).  
Despite the structural differences between these two molecules the binding of CoA 
induces a similar conformational change in the enzyme (21).  The pantothenate 
moiety of bound CoA has the same location and orientation as the bound 
pantothenate substrate.  The β-mercaptoethylamine moiety of CoA extends into the 
hydrophobic dome over the pantothenate-binding pocket.  Therefore, 
pantothenamide binding is predicted to induce a similar conformational change in 
the pantothenate-binding site.  A modelling solution of N5-Pan with the PanK-ADP-
pantothenate structure (with the pantothenate removed) supports the prediction that 
the hydroxyl of the pantothenamide is correctly orientated for the phosphorylation 
by binding in the same conformation as the pantothenate substrate.  The 
hydrophobic tail of the antimetabolite interacts with the hydrophobic domain, which 
binds the β-mercaptoethylamine moiety of CoA (6).  This is an exciting 
development as the model predicts that the design of future pantothenamide 
derivatives with hydrophobic groups that interact more strongly with the aromatic 
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residues of the hydrophobic roof over the pantothenate binding pocket will increase 
the affinity and specificity of the inhibitors/substrates (6).  
Like in E. coli, N5-Pan and N7-Pan are also effective antimicrobial agents against 
S. aureus but have a different mechanism of action (4).  The differences in the 
regulation of CoA in S. aureus and E. coli account for the difference in responses of 
these organisms to pantothenamides in the presence of pantothenate.  It has been 
shown (4) that the simultaneous addition of N5-Pan or N7-Pan and 50 µM 
pantothenate to the growth medium resulted in an upward shift of the minimal 
inhibitory concentrations (MICs) (8-fold for N5-Pan and 64-fold for N7-Pan).  This is 
an indication that the pantothenamides compete with pantothenate as a substrate in 
S. aureus.  When the same experiment was conducted in E. coli the addition of 
pantothenate only resulted in a 2-fold shift in the MIC of N5-Pan against E. coli (46).  
This suggests that the lack of feedback inhibition in S. aureus allows the 
accumulation of larger amounts of CoA and thus allows the organism to overcome 
the inhibitory effect of the pantothenamides more effectively (4). 
There are multiple targets for the pantothenamides in S. aureus and there are 
several important differences between this Gram-positive bacterium compared with 
the model E. coli system (46).  N7-Pan (MIC = 0.16 µM) is considerably more 
potent that N5-Pan (MIC = 25 µM) in S. aureus (4).  However, the efficacy of the 
two compounds is reversed in E. coli because of the export of N7-Pan from the cell 
via a TolC-dependent pump (46).  This means that the differences in the cell wall 
and the outer membrane define the selectivity of pantothenamides in Gram-positive 
and Gram-negative bacteria (4).  In both systems the pantothenamides are 
phosphorylated by PanK and incorporated into CoA and ACP analogs (4).  The 
accumulation of N7/N5-ACP results in inactivation of ACP and the inhibition of fatty 
acid synthesis.  Fatty acid synthesis is the most critical pathway blocked in both 
cases as shown by the ability of exogenous fatty acids to ameliorate the toxic 
effects of the pantothenamides (46).  However, Zhang et al. suggest the possibility 
of other targets of pantothenamides in S. aureus (4).  These researchers made 
another new discovery in that N7-Pan is also incorporated into Dcp (4).  Dcp is 
required for the biosynthesis of D-alanyl-lipoteichoic acid, a macroamphiphile 
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component of the Gram-positive cell wall-membrane complex (47).  Deactivation of 
Dcp would block D-alanine incorporation into the cell wall and this is critical for the 
function of the cell wall in pathogenic bacteria (36, 47, 48).  The inhibition of D-
alanine in S. aureus increases the sensitivity of this pathogen to charged 
antimicrobial peptides such as defensins as well as vancomycin (49, 50).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Interaction of ligands with the pantothenate-binding pocket. A, bound pantothenate 
(yellow) does not interact with the aromatic pocket formed by the side chains of residues Phe-244, 
Phe-247, Tyr-258, Phe-259, and Tyr-262 (all green) at the “top” of the pantothenate binding groove. B, 
N5-Pan (yellow) is shown docked into the pantothenate binding groove, and its binding is predicted to 
cause minimal perturbation of the aromatic pocket relative to pantothenate binding. C, bound CoA 
(yellow) interacts with several aromatic residues that rearrange to accommodate the relatively large 
bulk of the CoA molecule. For clarity, only the pantetheine moiety (PanSH) of CoA is shown (21).  
Reproduced with permission from Ivey et al. (2004) J. Biol. Chem., 279, 35622-35629. 
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Virga et al. (51), have recently conducted a study where they have synthesized a 
number of new antimetabolites based on the structures of the alkylpantothenamides 
and screened them as inhibitors against the pantothenate kinase enzymes of E. 
coli, A. nidulans, S. aureus and the murine analogue MmPanK1α.  In this paper the 
authors report that the pantothenamide analogues act as inhibitors of the 
pantothenate kinase reaction (51).  It is our belief that instead of inhibitors, they act 
as alternative substrates and that is why there is a decrease in the observed 
amount of phosphopantothenate formed.  We believe that this is also why the 
authors observe inhibition under assay conditions but not in live cells. 
3.7.  Significance of the Discovery of a Third PanK 
Analogue 
The discovery of a third analogue of pantothenate kinase would be a significant 
contribution to our understanding of how identical enzyme activities arise through 
convergent evolution.  Additionally, since genomic analysis studies suggest that the 
CoaX homologues account for the only PanK activity found in the pathogenic 
bacteria listed in Table 3.1, the immediate implications for the development of 
specific and directed antibacterial agents are evident.   
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 C h a p t e r  4  
Characterization of the First Type III 
Pantothenate Kinase∗ 
4.1.  Introduction 
In spite of our current knowledge of CoA biosynthesis in general and PanK 
enzymes in particular the identification of this activity remains elusive in a 
subset of pathogenic bacteria, including Helicobacter pylori.  This fact was 
highlighted in two recent studies, both of which used a comparative genomics 
approach to reconstruct the universal CoA biosynthetic pathway in 
representative organisms of all kingdoms (1, 2).  Among these, H. pylori and 
Pseudomonas aeruginosa are examples of bacteria in which no putative PanK 
similar to either known analogue could be found, even though the four 
remaining CoA biosynthetic enzymes were clearly represented.  Since PanK 
is an essential activity in these organisms, this suggested that at least one 
additional, uncharacterized analogue of PanK exists. 
A recent patent application has claimed to have identified a gene sequence 
which, when cloned in trans, can suppress the effects of an E. coli 
temperature-sensitive mutant defective in PanK activity (3).  Interestingly, this 
gene (yacB) was identified from the Bacillus subtilis genome; although 
similarity-based searches predict that its yqjS gene encodes the expected 
model prokaryotic Type I PanK.   
                                                 
∗ The contents of this chapter has previously been published, and is reproduced here in 
modified format with permission from the American Society for Biochemistry and Molecular 
Biology (ASBMB). See Brand, L. A., and Strauss, E, (2005) Characterization of a New 
Pantothenate Kinase Isoform from Helicobacter pylori.  J. Biol. Chem., 280, 20185-20188. 
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In support of the suggested duplication of PanK activity interruption of the B. 
subtilis yqjS gene gave a normal growing phenotype.  However, a B. subtilis 
double deletion mutant lacking both the yqjS and yacB genes was not viable.  
These results indicate that simultaneous deletion of both genes is lethal to B. 
subtilis and that the yacB gene encodes for a protein with pantothenate 
kinase activity (3). 
Similarity-based genome searches using the yacB gene sequence identify 
homologues in a number of bacteria (Table 4.1).  A subset of these is similar 
to B. subtilis in that they also have gene sequences encoding for Type I 
PanKs.  The rest consists of mainly pathogenic bacteria in which the yacB 
homologue accounts for the only recognizable PanK-encoding gene 
sequence.  These include H. pylori and P. aeruginosa in which the PanK-
encoding gene was missing (2) (see section 3.4), as well as others like 
Bordetella pertussis (the causative agent of whooping cough) and the 
category A biodefence pathogen, Francisella tularensis.  Interestingly, the 
yacB homologue in B. pertussis has been studied before, and was found to be 
an essential gene in this organism (4, 5).  However, these studies concluded 
that the gene product was involved in pertussis toxin production via interaction 
with a two component transcriptional regulator, BvgAS.  The gene was 
subsequently named baf, for Bvg accessory factor (Section 3.3).  Most yacB 
homologues are currently annotated as Bvg accessory factors, or as putative 
transcriptional regulators. 
In this chapter we report the cloning, overexpression and characterization of 
the yacB gene product from B. subtilis and its homologue from H. pylori, and 
demonstrate that these proteins have pantothenate kinase activity.  We chose 
to study H pylori because it is a medically relevant organism causing peptic 
ulcer disease and inflammation in the stomach known as gastritis.  H. pylori 
causes more than 90% of duodenal ulcers and up to 80% of gastric ulcers.  
Before 1982, when this bacterium was discovered, spicy food, stress and 
lifestyle were considered the major causes of ulcers.  After the discovery of 
this bacterium treatment measures were far more beneficial as patients were 
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treated with antibiotics instead of medication to relieve ulcer related 
symptoms.  Shockingly, approximately two-thirds of the world’s population is 
infected with H. pylori (6).  This statistic highlights H. pylori’s importance as an 
organism for further research.   
Table 4.1 
Selection of organisms predicted to have a Type III pantothenate kinase a 
In addition to a Type I PanK As the only PanK activity 
Bacillus halodurans Aquifex aeolicus 
Bacillus subtilis Bordetella pertussisi Tohama 
Mycobacterium avium Borrelia burgdorferi 
Mycobacterium bovis Campylobacter jejuni 
Mycobacterium leprae Clostridium botulinum 
Mycobacterium microti Deinococcus radiodurans 
Mycobacterium tuberculosis Francisella tularensis (Livermore) 
Listeria monocytogenes Helicobacter pylori 
Rhodobacter capsulatus Neisseria meningitidis 
Rhodobacter sphaeroides Porphyromonas gingivalis 
Streptomyces coelicolor Pseudomonas aeruginosa 
 Synechocystis sp.  PCC 6803 
 Thermotoga maritima 
 Treponema pallidum 
 Xylella fastidiosa 
aPredictions were made using the SEED tool (http://TheSEED.uchicago.edu/FIG/index.cgi) 
 
Our results show that in comparison to the Type I and Type II PanKs these 
CoaX3 enzymes exhibit distinctly different characteristics, suggesting that they 
are the first characterized examples of a third (Type III) PanK analogue.  
These findings have important implications for our continued effort in 
identifying new drug targets in pathogenic bacteria, as well as for our 
understanding of the convergent evolution4 of key metabolic enzymes. 
                                                 
3 The authors of the patent referred to above (7) called the product of the yacB gene CoaX.  We 
shall also use this nomenclature to refer to Type III PanK enzymes. 
4 Convergent evolution is the process whereby a similar character evolves independently in two 
species.  It is also a synonym for analogy; that is, an instance of a convergently evolved 
character, or a similar character in two species that was not present in their common ancestor 
(8). 
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4.2. Results and Discussion 
4.2.1.  Cloning, Purification and Expression of Type III PanKs 
The putative CoaX proteins from B. subtilis (BsCoaX) and H. pylori (HpCoaX) 
were prepared by independently cloning the respective genes into 
overexpression vectors coding for N-terminal His6-tagged fusion proteins.  In 
addition to the CoaX genes, E. coli PanK and the S. aureus PanK were also 
cloned according to published methods (9, 10).  The vectors were transformed 
into E. coli BL21 Star(DE3) and the proteins overexpressed and purified using 
immobilized metal affinity chromatography.  The purity of the proteins was 
verified SDS-PAGE analysis (Figure 4.1).   
 
 
 
 
 
 
 
FIGURE 4.1.  SDS-PAGE analysis of the overexpression and purification of BsCoaX and 
HpCoaX.  The B. subtilis yacB gene and the HP0862 gene from H. pylori were cloned and 
overexpressed in E. coli.  The resulting proteins, named BsCoaX and HpCoaX respectively, 
were purified by immobilized metal ion chromatography.  Lane 1: Molecular weight markers 
(kDa).  Lane 2: BsCoaX cell-free extract.  Lane 3: Purified BsCoaX fraction.  Lane 4: HpCoaX 
cell-free extract.  Lane 5: Purified HpCoaX fraction. 
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4.2.2.  Complementation 
The Hp- and BsCoaX genes were subcloned from pET28a-HpCoaX and 
pET28a-BsCoaX into pENTR4NT producing the plasmids pENTR4NT-
HpCoaX and pENTR4NT-BsCoaX respectively.  By means Gateway 
technology (Invitrogen) these two genes were subsequently cloned into 
pBAD-DEST49.  While pET28a is our preferred expression vector, we decided 
that for complementation the pBAD-DEST49TM GatewayTM vector would be 
more suitable due to a number of special features.  Chief among these is the 
use of the araBAD (PBAD) promoter that provides tight, dose-dependent 
regulation of heterologous gene expression based on the concentration of L-
arabinose in the media.  In addition, the tight regulation of PBAD by araC is 
useful for the expression of potentially toxic or essential genes.   
Once the gene of choice is cloned into this vector it becomes an expression 
vector designed for the regulated expression of N-terminal HP-thioredoxin 
fusion proteins in E. coli.  The resulting plasmids, pBAD-Exp-HpCoaX and 
pBAD-Exp-BsCoaX were transformed into competent E. coli DV62 (EcDV62) 
cells.  In addition, pBAD-Exp-pGUS (negative control) was also transformed 
into EcDV62.  The E. coli strain DV62 is temperature sensitive with respect to 
pantothenate kinase function.  This means that at temperatures of 42˚C and 
above the mutant is unable to biosynthesize CoA and cannot survive, while it 
grows normally at 30˚C.  Therefore, unless an active PanK-encoding gene is 
cloned in trans in this cell strain it will not survive when grown at 42˚C.   
We performed the complementation experiment by streaking the 
transformants onto two identical plates, and incubating them separately at 
30˚C and 42˚C.  At 30˚C all transformants survived, while at 42˚C only those 
containing the coaX gene survived (Figure 4.2).  This observation supports 
the hypothesis that the coaX gene encodes a protein with pantothenate 
kinase activity.  
The plate-based complementation experiment highlights one of the drawbacks 
of doing complementation studies on solid media.  It is apparent that the cell 
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density in the separate thirds of the plate is not equal (Figure 4.2).  Although 
this is more apparent on the 42˚C plate it is also evident on the plate at 30˚C.  
We drew the conclusion that this may be due to an unequal number of cells 
being transferred to the plate when it is initially streaked.  This could give a 
skewed and inconclusive result.  However, it is also possible that HpCoaX 
expresses at higher levels or is more active than BsCoaX and for this reason 
is better able to complement the temperature sensitive PanK mutant.   
 
 
 
 
 
 
 
 
 
Figure 4.2.  Complementation studies.  BsCoaX (bottom right), HpCoaX (top center) and a 
negative control (pGUS, bottom left) were transformed into an E. coli strain that is temperature 
sensitive in terms of pantothenate kinase activity.  At 30˚C the temperature sensitive PanK 
could still function and all transformants were able to grow.  At 42˚C only the transformants 
containing the coaX gene survived.  This means that the coaX gene is capable of 
complementing a temperature sensitive PanK mutant and therefore has PanK activity. 
 
       30˚C                                                         42˚C
Chapter 4:  Characterization of the First Type III Pantothenate Kinase 58 
 
We decided that it was more reliable to conduct complementation in liquid 
media and to measure the increase in optical density of the growth media at 
600 nm.  The results indicate that both HpCoaX and BsCoaX complement for 
pantothenate kinase activity.  As expected of the negative control, pGUS does 
not complement the temperature sensitive mutant and the cells do not grow at 
42˚C (Figure 4.3). The results indicate that HpCoaX complements the 
temperature sensitive mutant far sooner than BsCoaX.  This supports the 
hypothesis that the HpCoaX protein is either more soluble or expresses at 
higher levels than the BsCoaX protein, and indicates that the difference in cell 
density observed in the plate-based complementation study was a real event, 
and not due to a streaking inconsistency.  
 
Figure 4.3.  The coaX genes from B. subtilis and H. pylori are able to complement the 
pantothenate kinase activity of a temperature sensitive mutant.  Expression vectors 
containing BsCoaX, HpCoaX and pGUS (negative control) were transformed into the E.coli 
DV62 temperature sensitive mutant cell line.  These vectors were cultured in minimal at 42°C 
and the increase in absorbance was measured over time. 
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4.2.3.  Kinetic Characterization of Type III PanKs 
The purified proteins were assayed for their ability to catalyze the ATP-
dependent phosphorylation of pantothenate using a two enzyme-coupled 
assay that links the production of ADP to the oxidation of NADH.  This allows 
the enzyme activity to be measured continuously by monitoring the change in 
A340.  The assay was performed by varying the pantothenate concentration at 
a number of set ATP concentrations, and determining the initial rates of the 
reaction for each protein (Figure 4.4).  The results clearly show that both 
CoaX proteins have PanK activity.   
The initial rate data were used to determine the kinetic parameters of the 
enzymes by performing global non-linear fits using the most general form of 
the equation describing a bireactant mechanism (11).  The results are 
summarized in Table 4.2 which also shows the kinetic parameters of the 
model prokaryotic Type I PanK, E. coli (EcCoaA) (12), the eukaryotic PanK 
from Aspergillus nidulans (AnPanK) (13) and the recently characterized 
atypical Type II PanK from S. aureus (SaCoaA).   
Table 4.2.  Kinetic parameters of the three characterized pantothenate kinase isoforms 
Analogue Enzyme kcat (s-1) Substrate KM (µM) 
kcat/KM 
(mM-1.s-1) 
Pantothenate 36 ± 4 8.38 ± 3.69 Type I 
(Prokaryotic) 
EcCoaAa 0.30 ± 0.13 
ATP 136 ± 15 2.22 ± 0.98 
Pantothenate 60 32.6 
AnPanKb 1.95 
ATP 145 13.5 
1.73 Pantothenate 23 75.2 
Type II 
(Eukaryotic) 
SaCoaAc 
1.56 ATP 34 45.9 
Pantothenate 168 ± 27 12.58 ± 2.27 
BsCoaX 2.12 ± 0.17 
ATP 3050 ± 520 0.70 ± 0.13 
Pantothenate 101 ± 26 20.6 ± 5.9 
Type III 
(CoaX-like) 
HpCoaX 2.09 ± 0.26 
ATP 9590 ± 2140 0.21 ± 0.05 
aE. coli CoaA; apparent kinetic parameters taken from ref. (12) 
bA. nidulans PanK; apparent kinetic parameters taken from ref. (13) 
cS. aureus CoaA; apparent kinetic parameters taken from ref. (14) 
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Figure 4.4.  Initial rate plots of BsCoaX (top) and HpCoaX (bottom).  Iinitial rates of BsCoaX 
against pantothenate concentration at an ATP concentration of 0.5 mM ( ), 1.0 mM ()), 2.0 
mM (!), 3.0 mM ("),5.0 mM (f) and 10.0 mM (h) respectively.  Initial rates of HpCoaX 
against pantothenate concentration at an ATP concentration of 1.0 mM ( ), 2.0 mM ()), 3.0 
mM (!), 5.0 mM ("), 10.0 mM (f) and 15.0 mM (h) respectively.  Symbols show the average 
of three replicates, with error bars indicating the standard deviation.  4.5 µg of PanK enzyme 
was used per reaction.  Curves show fits of the individual data sets to the Michaelis-Menten 
equation. 
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When one examines the numerical kinetic data from the various PanK 
analogues, the KM values for pantothenate are all within the same range.  The 
CoaX enzymes KM values are slightly higher but not significantly so.  
However, the same cannot be said for the ATP, where the KM-values for the 
CoaX proteins are in the millimolar range. The affinity of HpCoaX for ATP is 
especially low with a KM value of nearly 10 mM.  The KM of HpCoaX differs 
from that of the well-characterized E. coli PanK analogue (EcCoaA) by a 
factor of over 70!  Such large KM values can be rationalized in the case of the 
BsCoaX enzyme that duplicates an activity already embodied by the more 
typical Type I PanK.  However, since HpCoaX depends exclusively on this 
PanK for its CoA biosynthetic needs the question arises as to whether it uses 
an alternate phosphate donor in the reaction catalyzed by this enzyme. 
4.2.4.  Testing the Efficacy of Alternate Phosphoryl Donors 
The low ATP specificity constant of BsCoaX and HpCoaX suggested that 
these enzymes might have a preference for other phosphoryl donors in the 
biosynthesis of 4’-phosphopantothenate.  This proposal was tested by 
incubating the enzymes with pantothenate and a range of activated and non-
activated phosphate-containing substrates.  These included the three other 
ribonucleotide 5’-triphosphates (GTP, CTP and UTP), PEP, acetyl- and 
carbamoylphosphate, and phosphoserine and -threonine.  The latter two 
molecules were tested because of the recent discovery and characterization 
of a phosphotransferase enzyme, which catalyzes the transfer of a phosphoryl 
group from phosphoserine to homoserine via an activated phosphoenzyme 
intermediate (15).  Other examples of similar reactions have also been 
described (16).  The reaction mixture with PEP was subsequently analyzed by 
the two enzyme-coupled assay, while the rest of the reaction mixtures were 
analyzed by ESI-MS for the presence of 4’-phosphopantothenate.  The results 
were compared to mixtures containing ATP as well as to control reactions with 
E. coli PanK.  Only CTP and GTP could substitute for ATP in the case of 
HpCoaX, albeit to a lesser extent (Figure 4.5).  No other phosphoryl donor 
was active in the reactions catalyzed by BsCoaX.  This strongly points to ATP 
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as the cognate phosphoryl donor in the PanK reaction catalyzed by CoaX 
enzymes.  Results for B. subtilis and E. coli are not shown. 
 
Figure 4.5.  ESI-MS result for HpCoaX using phosphothreonine (line 1), phosphoserine 
(line 2), UTP (line 3), GTP (line 4), CTP (line 5) and ATP (line 6) as phosphate donors for 
the pantothenate kinase reaction.  Only GTP and CTP can substitute for ATP, albeit to a 
lesser extent (note that the intensity of the base peak for these two nucleotides is an order of 
magnitude lower than that of ATP).  Also shown are the structures and molecular weight 
analysis for pantothenate and phosphopantothenate. 
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4.2.5.  Inhibition of Type III PanKs by CoA and Acetyl-CoA 
With the exception of the recently characterized S. aureus PanK enzyme (14), 
all other known PanKs are inhibited by CoA or its thioesters.  The extent of 
inhibition is system dependent: prokaryotic Type I PanKs exhibit greater 
inhibition by free CoA than its thioesters, while the activity of eukaryotic Type 
II PanKs is affected more by the CoA thioesters acetyl- and malonyl-CoA.  In 
both cases the inhibition serves to regulate the intracellular CoA concentration 
by affecting the flux through the pathway.  To determine whether a similar 
effect can be observed with the CoaX enzymes reactions containing 
increasing amounts of CoA or acetyl-CoA were assayed for PanK activity 
(Figure 4.6).  The experiment was also performed with E. coli PanK, which 
has a well-described inhibition profile (17), for comparison.  Our results show 
that while E. coli PanK demonstrates inhibition by CoA and to a lesser extent 
by acetyl-CoA as expected, neither of the CoaX enzymes is affected.  This 
result is surprising, since the inhibition of PanK by CoA and its thioesters was 
until recently considered to constitute a common mechanism for the regulation 
of intracellular CoA levels in all organisms.  The fact that the S. aureus PanK 
enzyme is not subject to such regulation has been rationalized in terms of the 
unique physiology of this organism that depends on CoA and a NADPH-
dependent CoA reductase to maintain the intracellular redox balance (18, 19) 
(Discussed in Section 3.3.1).   
A possible explanation for the unusual steady state kinetic properties, 
especially the high KM value for ATP, of H. pylori is that the low specificity for 
ATP may exert some effect on the rate of CoA biosynthesis in this organism.  
Futhermore, the CoA biosynthesis may be directy affected by the cellular ATP 
and pantothenate levels and thus coupled to the energy status of the cell. 
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Figure 4.6.  Inhibition of EcCoaA, HpCoaX and BsCoaX by CoA and acetyl-CoA.  Inhibition 
of the pantothenate kinase activity of EcCoaA ( ,)), BsCoaX (!,") and HpCoaX (f,h) in 
the presence of CoA (closed symbols) and acetyl-CoA (open symbols).  Symbols show the 
average of three replicates, with error bars indicating the standard deviation.  Reaction mixtures 
contained 500 µM pantothenate, ATP (5.0 mM for BsCoaX, 10.0 mM for HpCoaX and 1.5 mM 
for EcCoaA), 20 mM KCl, 10 mM MgCl2, 2 mM PEP, 0.3 mM NADH, 5 U of lactate 
dehydrogenase, 2.5 U of pyruvate kinase and 4.5 µg of the PanK enzyme in 100 mM HEPES 
(pH 7.6).  CoA and acetyl-CoA were added at concentrations between 10 and 500 µl and the 
reaction was initiated by the addition of pantothenate. 
4.2.6.  Effect of Pantothenamide Antimetabolites on Type III 
PanKs  
Recent studies on the E. coli PanK and S. aureus PanK enzymes have shown 
that N-alkylpantothenamides like N-pentyl and N-heptylpantothenamide 
(Figure 3.2, Section 3.4) act as antimicrobial agents through their action as 
CoA antimetabolites (9, 10, 14).  These compounds were found to act as 
substrates of the CoA biosynthetic enzymes in both E. coli and S. aureus, 
where they are converted to inactive CoA analogues which inhibit a number of 
cellular targets, especially fatty acid biosynthesis (10, 14, 20).  To test whether 
this was also the case with CoaX enzymes, N-pentylpantothenamide was 
substituted for pantothenate in reaction mixtures and the reactions assayed by 
Chapter 4:  Characterization of the First Type III Pantothenate Kinase 65 
 
the two enzyme-coupled system.  No activity could be detected using N-
pentylpantothenamide at concentrations of up to 0.5 mM (data not shown).  
To test if the compound was an inhibitor of the enzyme, the activity of CoaX 
enzymes was assayed in the presence of increasing concentrations of N-
pentylpantothenamide.  No effect was observed (data not shown).  It has been 
suggested (14) that the two enzyme-coupled system is not as sensitive as the 
radioactive-based assay employed in other studies as it reportedly failed to 
detect that N-pentylpantothenamide was a substrate for S. aureus PanK (9).  
However, in our hands we clearly detect activity when assaying S. aureus 
PanK in the presence of N-pentylpantothenamide by this method, suggesting 
that sensitivity is not a factor. 
4.2.7.  Gene Cluster Analysis in Support of Functional 
Characterization  
The conservation of gene clusters across genomes can often be applied to 
infer gene function (21).  To apply this technique to CoaX enzymes the genes 
coding for these proteins were aligned across a set of genomes and the 
respective gene clusters analyzed for the presence of other CoA and 
pantothenate biosynthetic genes (Figure 4.7).  The results show that in 
Mycobacterium spp., Streptomyces coelicolor, Moorella thermoacetica and 
Francisella tularensis genes encoding CoaX proteins are found associated 
with two genes involved in pantothenate biosynthesis (combinations of 
pantothenate synthetase, aspartate 1-decarboxylase or ketopantoate 
hydroxymethyltransferase), while in Bdellovibrio the cluster contains these 
three pantothenate biosynthetic genes as well as the putative 
phosphopantothenoylcysteine synthetase/decarboxylase-encoding gene.  
Such clustering provides strong genetic support for the direct involvement of 
CoaX proteins in CoA biosynthesis. 
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Figure 4.7.  Cluster analysis of the predicted coaX gene in selected organisms.  Selected 
chromosomal contigs containing a gene predicted to encode a Type III pantothenate kinase 
(labelled coaX) were aligned to visualize gene clustering on the chromosome.  Other genes 
involved in pantothenate and CoA biosynthesis are panB (ketopantoate 
hydroxymethyltransferase), panC (pantothenate synthetase), panD (aspartate 1-decarboxylase) 
and coaBC (phosphopantothenoylcysteine synthetase/decarboxylase).  Other unrelated genes 
are also labelled using standard nomenclature for sequences with known or predicted functions, 
or using letters A, B, and C for unknown hypothetical proteins which share high sequence-
similarity.  The alignment was prepared from data modified from the SEED tool 
(http://TheSEED.uchicago.edu/FIG/index.cgi). 
4.3.  Conclusion 
In this chapter we have cloned, overexpressed and characterized two 
homologous proteins from B. subtilis and H. pylori and demonstrated that they 
have pantothenate kinase activity.  However, these proteins do not share 
sequence similarity with the other two known PanK analogues.  They also 
exhibit unique kinetic characteristics, showing low specificity constants for 
ATP and no regulation by CoA and its thioesters.  They do not utilize the 
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alkylpantothenamides as substrates, nor are they inhibited by them.  These 
properties all distinguish them from the other PanK analogues, and strongly 
suggest that they are the first characterized examples of a third analogue of 
the PanK enzyme.  These Type III PanKs represent the only recognizable 
pantothenate kinase activity in a variety of organisms, including the pathogens 
H. pylori and P. aeruginosa, in which no candidate PanK-encoding genes 
could be identified to date.  It is still unclear what advantage, if any, these 
enzymes confer upon the mainly pathogenic organisms that harbour them.   
4.4.  Experimental Procedures 
4.4.1.  Materials and Methods 
All chemicals were purchased from Aldrich, Sigma or Fluka and were of the 
highest purity.  Other materials were from the following suppliers: Pyruvate 
kinase and lactate dehydrogenase enzymes from Roche; restriction 
endonucleases, Pfu and Taq DNA polymerase from Fermentas; Quick ligation 
kit from New England Biolabs (NEB), Bradford dye reagent and BSA protein 
standards from Biorad; oligonucleotides from Inqaba Biotechnology (Pretoria, 
South Africa); and HiTrap columns from Supelco.  B. subtilis genomic DNA 
was purified from B. subtilis 168, obtained from ATCC.  H. pylori genomic 
DNA was a gift from Paul van Helden and Rob Warren (Department of 
Medical Biochemistry, Stellenbosch University).  Automated DNA sequencing 
was performed by Inqaba Biotechnology (Pretoria, South Africa).  Proteins 
were purified on an ÄKTA Prime instrument (Amersham Biosciences).  Large-
scale centrifugation was done on a Heraeus Multifuge® 3S/3S-R.  
Centrifugation on a smaller scale was conducted on a Heraeus Biofuge pico 
centrifuge.  Enzyme assays were performed on a Multiskan Spectrum 
multiplate spectrophotometer (ThermoLabsystems), using an extinction 
coefficient of 6220 M-1.cm-1 for NADH.  ESI-MS analyses were performed at 
the Central Analytical Facility at Stellenbosch University on a Waters 
Micromass Q-TOF Ultima API mass spectrometer.  The SaCoaA expression 
plasmid was a gift from Cynthia Kinsland (Department of Chemistry and 
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Chemical Biology, Cornell University).  The SaCoaA protein was purified 
according to published methods, using BL21 (DE3) (Novagen) as expression 
strain (9).  EcCoaA was prepared by published methods (10).  All curve-fitting 
analyses were performed using SigmaPlot 9.0 (Systat software).  E. coli DV62 
was obtained from the E. coli Genetic Stock Center (CGSC) at Yale 
University)  
4.4.2.  Construction of Expression Vectors 
The B. subtilis coaX (yacB) gene was amplified by PCR from B. subtilis 168 
genomic DNA using Pfu DNA polymerase and the following primers: 5’-
CAAAAGTGGTGACATATGTTGTTACTGGTTATC-3’ (forward primer), 
introducing an NdeI site (underlined) at the start of the gene, and 5’-
CCATATCAGTCGTTCTCGAGGCATAAGCCCGAAC-3’ (reverse primer), 
introducing an XhoI site (underlined) at the end of the gene.  The H. pylori 
HP0682 gene was amplified by PCR from H. pylori genomic DNA using Taq 
DNA polymerase and the following primers: 5’-
ATAAGAAGTAGGCATATGCCAGCTAGGC -3’ (forward primer), introducing 
an NdeI site (underlined) at the start of the gene, and 5’-
ATGCCCAAAAAACTCGAGTTGTGCATC-3’ (reverse primer), introducing an 
XhoI site (underlined) at the end of the gene.  The resulting PCR products 
were digested with NdeI and XhoI and ligated to NdeI/XhoI-digested pET28a 
expression vector (Novagen) using the NEB Quick Ligation Kit.  The 
sequences of the resulting plasmids, named pET28a-BsCoaX and pET-28a-
HpCoaX respectively, were verified by automated DNA sequencing.  The 
expression plasmids allow for the production of the proteins as N-terminal 
His6-tagged fusion proteins.  The detailed method for the cloning of these 
plasmids is given below in 4.4.2.1. 
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4.4.2.1.  Standard Cloning Procedure 
Design of Primers 
When cloning from genomic DNA, in most cases (unless stated otherwise) we 
introduced an NdeI (CAT-ATG) site in the forward primer and an XhoI (CTC-
GAG) site in the reverse primer.  The NdeI site is inserted in the forward 
primer so that the ATG is the starting Met of the protein.  If a mutation is 
introduced then it is kept 12 or more bases from the ‘3 end of the primer.  All 
primers are checked for self-annealing.  If possible, the ‘3- end of the primer 
ends in G or C.  The ‘3 end of the primer is not terminated in more than 2 of 
the same base pairs in a row. 
PCR Reaction 
The PCR reaction is set up as follows.  If the reaction yields no products at the 
suppliers specified magnesium concentration, then it is repeated with differing 
MgSO4 concentrations.  If this is the case then the amount of water is 
decreased so that the total volume remains 25 µl.  The PCR reactions were 
performed in a 250 µl reaction vessel as follows: 
2.5 µl  10 x amplification buffer 
1 µl   dNTP mix (10 mM) 
1 µl   MgSO4 (25 mM)  
1 µl   Forward Primer (25 µM)  
1 µl   Reverse Primer (25 µM) 
X µl   Genomic DNA (2 ng) 
0.5 µl  Pfu DNA polymerase (X U/ µl) 
18 – X µl   Sterile water 
25 µl   TOTAL 
 
The PCR products were run on a MyCyclerTM Thermal Cycler (BioRad) using 
the protocol illustrated below: 
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PCR Program: 
 
 
 
 
 
 
 
 
 
 
DNA Electrophoresis 
Unless stated otherwise, 10 x loading buffer (0.25 % bromophenol blue, 49.5 
mM TRIS pH 7.6 and 60 % glycerol) was added to samples loaded on 
agarose gels.  All gels were 1 % agarose made up with 1 x TAE buffer (40 
mM Tris-acetate, 1 mM EDTA) and run at 75 V (PowerPac from Biorad).  The 
samples were run against 1 µg 2-log ladder (New England BioLabs Inc.)  The 
gels were stained in 50 ml of TAE buffer supplemented with 5 µl SYBR® Gold 
(Molecular probes, Invitrogen detection technologies).  DNA visualization took 
place with the help of a Dark Reader Transilluminator (Molecular probes Inc.)  
The products of the PCR were excised from the gel and purified with the 
Perfectprep® Gel Cleanup Kit (Eppendorf).   
Digestions: 
The purified PCR product and the pET28a expression plasmid (Novagen) 
were digested with NdeI (New England Biolabs) and XhoI (Inqaba 
Biotechnology).  The digestion mixture contained the following: 
2 µl  XhoI 10 x reaction buffer (contains BSA to final concentration of 0.1 mg/ml) 
14 µl  Purified PCR product/plasmid (~ 250 ng) 
1 µl  sterile water 
1 µl  NdeI (20U/µl) 
2 µl  XhoI (10U/µl) 
20 µl  TOTAL 
The digests were incubated at 37˚C for 2 hours.   
∞ 
4 ˚C 
30 sec 
55 ˚C 
94 ˚C 94 ˚C 
1.5 min 
30 sec 2 min 68 ˚C 68 ˚C 
6 min 
1 x (30 x) 1 x 1 x 
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After incubation, the NdeI/XhoI cut plasmid and PCR products underwent 
electrophoresis and were excised from the gel.  The gel bands were purified 
with the Perfectprep® Gel Cleanup Kit (Eppendorf).   
In order to determine the concentration of the digested plasmid and PCR 
DNA, 5 µl of each were run on a gel.  They were run against the 2-log ladder 
containing bands of known concentration.  By comparing the intensity of the 
sample DNA with that of the ladder it is possible to determine the 
concentration of the sample DNA in ng/µl.  This value was converted to 
fmoles/µl for the purpose of the ligation reaction. 
Ligation of plasmid and PCR DNA 
The concentration of the digested plasmid is not always equal to that of the 
digested PCR product.  We used a 1:1 concentration ratio of plasmid to insert 
DNA in our ligation reaction.  Ligations were performed using the Quick 
LigationTM Kit (New England BioLabs).  This kit ensures that the entire ligation 
protocol is completed in 5 minutes and is highly reliable.  Except for halving 
the reaction volume, the protocol was carried out according to the 
manufacturer’s specifications. 
Transformation 
The products of the ligation reaction were transformed into Mach1 competent 
cells (Invitrogen). 
Making Competent Cells: 
From frozen stock the cell line of ones choice is streaked on Luria Bertani (LB) 
agar (biolab – Merck) plates.  The plates are incubated at 37 ˚C overnight.  A 
single colony is selected from the plate and used to inoculate 5 ml of (LB) 
broth (biolab – Merck).  This culture is grown overnight at 37 ˚C in a shaking 
incubator (200 rpm) and in turn used to inoculate 500 ml of LB broth in a 2L 
flask (at a ratio of 1:1000, i.e. 5 ml in 500 ml of media).  This is grown at 37 ˚C 
in a shaking incubator (200 rpm) until the OD600 = 0.5 – 0.6 nm (~ 2 hours).  
The cells are collected by centrifugation at 4500 x g for 30 minutes at 4 ˚C.  
The supernatant is discarded and the cells resuspended in 100 ml of ice cold 
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100 mM MgCl2.  Thereafter they are incubated on ice for 30 minutes.  The 
cells are centrifuged at 4500 x g at 4 ˚C for 10 minutes, the supernatant 
discarded, and re-suspended in 10 ml of 100 mM CaCl2-15 % glycerol (ice 
cold).  The competent cells are then aliquoted (170 µl/tube) into the pre-chilled 
tubes and stored at –80 ˚C. 
Transformation Procedure 
The frozen competent cells are thawed on ice for 5 to 10 minutes.  80 µl of the 
competent cells are added to the ligation reaction.  The reaction is incubated 
on ice for 30 minutes and then heat shocked at 42 ˚C for 45 seconds.  This is 
followed by a cooling step on ice for 5 minutes. Thereafter, 900 µl of LB is 
added to the transformation mixture and it is incubated in a shaking incubator 
(200 rpm) for 1 hour at 37 ˚C.  The cell pellet is collected by centrifugation at 
8000 rpm for 4 minutes.  Using a pipette 850 µl of the supernatant is removed 
(being careful not to disturb the cell pellet) and the cells are then re-
suspended in the remaining media.  This is plated onto an LB agar plate 
containing the relevant antibiotic.  Unless stated otherwise the concentrations 
of antibiotics used are as follows: 
Kanamycin:    30 mg/L 
Ampicillin:    100 mg/L 
Tetracycline:    12.5 mg/L 
 
The cells are spread evenly on the plate by means of sterile glass beads.  The 
plate is Incubated at 37 ˚C overnight. 
Screening of Clones 
Two screens are conducted to check for the insertion of the gene of interest 
into the plasmid.  Firstly, a screening gel is run.  From the results of the 
screening gel, colonies are chosen and plasmids prepared from these 
colonies.  The second method follows the first and involves the digestion of 
these plasmids with the original restriction enzymes to check for an insert of 
the correct size. 
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Screening Gel 
Firstly, 25 µl of lysis solution 1 (30 mM Tris pH 8.0, 5 mM Na2EDTA, 50 mM 
NaCl, 20 % sucrose, 0.05 mg/ml lysozyme and 0.05 mg/ml RNAse) is added 
to each 1.5 ml microcentrifuge tube.  Using a sterile toothpick, a single colony 
is scraped from the LB plate and re-suspended in solution 1.  Thereafter the 
toothpick is streaked on a new LB plate that is marked with a numbered grid 
so that each screen can be identified at a later stage.  This plate is called the 
reporter plate.  The process is repeated with each colony.  The tubes are 
vortexed briefly followed by addition of 10 µl of solution 2 (1 x TAE, 2 % SDS, 
5 % sucrose and 2 mg/ml bromophenol blue).  The microcentrifuge tubes are 
vortexed to evenly mix their contents.  Thereafter, 20 µl from each tube is 
loaded on a 1 % agarose gel.  Loading must be done very carefully as the 
solution becomes viscous and is difficult to load.  Undigested pET28a is 
loaded as a standard.  The gel is run at 75 V. 
Positive screens are those that are bigger than the plasmid standard loaded 
as a marker.  A representative of the positive screens (recorded on the 
reporter plate) is used to inoculate 5 ml of media (containing the relevant 
antibiotic) and grown in a shaking incubator (200 rpm) at 37 ˚C overnight. 
Digestion Screen 
The above overnight culture is used to purify a plasmid.  This is done with the 
help of the FastPlasmidTM Mini kit (Eppendorf).  The purified plasmid is 
digested with the original restriction enzymes used to cut it before ligation (in 
most cases NdeI and XhoI).  The digestion is conducted in the same was as 
above.  The digestion products are run on a 1 % agarose gel against the 2-log 
ladder.  Positive clones are those that produce inserts the size of the gene of 
interest. 
Sequencing 
The positive clone is transformed into Mach1 and plated onto a LB plate 
containing the relevant antibiotic.  The plate is sent to Inqaba Biotechnology 
(Pretoria) who confirm the clone by automated DNA sequencing.   
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On confirmation the clone is stocked at –80 ˚C (900 µl of overnight culture, 
100 µl 80 % glycerol).  In addition, the plasmid is transformed into E. coli BL21 
(Star)DE3 for expression. 
4.4.3.  Complementation Studies 
4.4.3.1.  Cloning of the Expression vectors 
The pENTR4 vector is commercially available from Invitrogen.  This vector is 
used as an Entry clone for LR reactions in the GatewayTM cloning system.  
The “L” and “R” of the LR reaction are derived from the attL and attR sites of 
the plasmids involved in the reaction. 
GatewayTM Cloning Technology is a universal system for the cloning and 
subcloning of DNA sequences.  This facilitates gene function analysis and 
protein expression.  The LR reaction is used to create an Expression clone.  
The first step is to get the gene of interest into an Entry clone.  Thereafter, the 
gene is cut on either side within the attL sites in the Entry clone and ligated 
into the corresponding attR sites in the Destination vector.  This single step 
reaction creates an Expression clone and is very convenient. 
We needed a modified pENTR4 entry clone for our LR reaction.  Our genes 
were cloned into pET28a and flanked by NdeI and XhoI.  The commercially 
available pENTR4 does not contain an NdeI site.  We performed a 
mutagenesis PCR reaction to replace the NcoI site in pENTR4 with NdeI.  We 
used the QuikChange® Site-Directed Mutagenesis Kit from Stratagene.  The 
primers used for the mutagenesis PCR were as follows (NdeI site underlined): 
Forward Primer:  5’-AAGCAGGCTCCCATATGGGAACCAATTCAGTCGACTGGATC-3’ 
Reverse Primer:  5’-GATCCAGTCGACTGAATTGGTTCCCATATGGGAGCCTGCTT-3’ 
The resulting plasmid was named pENTR4N (N for NdeI).  This plasmid was 
further modified to contain the tetracycline resistant gene.  The tetracycline 
resistant gene was cloned from pBR322 vector (Promega) by PCR reaction.  
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The forward primer introduced a PstI site (underlined), while the reverse 
primer introduced a PfIm site (underlined): 
Forward primer:  5’-GGCCCTTTCGTCTGCAGGAATTCTCATGTTTG-‘3 
Reverse primer:  5’-GATTGGCTCCAAAGGTTGGAGTGGTGAATCCG-‘3 
The resulting PCR product was digested with PstI and PfIm and ligated to 
PstI/PfIm-digested pENTR4N Entry clone using the standard cloning 
procedure described in 4.4.2.1.  The resulting plasmid was designated 
pENTR4NT (“N” for NdeI and “T” for tetracycline resistant gene) 
Thereafter, the coaX genes from H. pylori and B. subtilis were excised using 
NdeI and XhoI from pET28a-HpCoaX and pET28a-BsCoaX respectively and 
subcloned into NdeI/XhoI-digested pENTR4NT.  The resulting plasmids were 
designated pENTR4NT-HpCoaX and pENTR4NT-BsCoaX. 
All that remained was to perform the LR reaction to get the coaX genes into 
the Expression clone, pBAD-DEST49.  For each (HpCoaX and BsCoaX) the 
Entry clone (pENTR4NT-HpCoaX and pENTR4NT-BsCoaX respectively) was 
combined with pBAD-DEST49 as specified by the manufacturer and the LR 
reaction conducted.  Two Expression clones were created and termed pBAD-
Exp49-HpCoaX and pBAD-Exp49-HpCoaX.  These expression clones were 
used in the complementation studies.  In addition to these two clones, a third 
was made to serve as a negative control in the complementation studies.  An 
Entry clone named pENTR-gusTM comes with the LR reaction kit and this was 
used in an LR reaction with pBAD-DEST49 in the same way as the other two 
LR reactions.  All the Expression clones are ampicillin resistant. 
4.4.3.2.  Complementation 
The pBAD-Exp49-pGUS, pBAD-Exp49-HpCoaX and pBAD-Exp49-BsCoaX 
vectors were transformed into chemically competent E. coli DV62 cells 
(metB1, PanD2, CoaA15, zij::Tn10) (17).  This strain of E. coli is temperature 
sensitive in terms of pantothenate kinase activity and will only grow at 
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temperatures above 42˚C if a gene coding for PanK activity is cloned in trans 
in these cells.   
The transformations were plated onto LB ampicillin agar plates and grown 
overnight at 37˚C.  From the plates obtained, overnight cultures were made 
from single colonies in 5ml LB ampicillin broth and these overnight cultures 
were used to stock the plasmids at -80˚C.   
Complementation on Minimal Media Plates: 
Minimal media (E salts (1%), 0, 5% glycerol, 1 mg/ml methionine, 0.1 mg/ml 
thiamine) plates supplemented with β-alanine (10µM), 0.2% L-arabinose and 
100 mg/L ampicillin were divided into three.  Two plates were each streaked 
with pBAD-Exp-pGUS, pBAD-Exp-HpCoaX and pBAD-Exp-BsCoaX in 
EcDV62 from the -80˚C freezer stock.  One plate was incubated at 30˚C and 
the other at 42˚C for 48 hours.  The pGUS vector was used as negative 
control. 
Complementation in Liquid Media 
Corning 6-well, flat-bottomed cell culture plates (Sigma) were used.  To each 
well 4 ml of sterile minimal media (E salts (1%), 0, 5% glycerol, 1 mg/ml 
methionine, 0.1 mg/ml thiamine) supplemented with 10µM β-alanine, 0.2% L-
arabinose and 100 mg/L ampicillin was added.  The minimal media was 
inoculated with 10 µl of an overnight culture of the respective expression 
clones (the experiments were done in duplicate).  The absorbance readings 
were read by a VarioskanTM spectrophotometer (ThermoLabsystems) at 600 
nm every 30 minutes for 52 hours. 
4.4.4.  Expression and Purification of Recombinant Proteins 
pET28a-BsCoaX and pET28a-HpCoaX were transformed into E. coli BL21 
Star(DE3) (Invitrogen).  LB media (500 ml) was supplemented with 30µg/ml 
kanamycin sulfate and inoculated with overnight cultures of either BL21 
Star(DE3)/pET28a-BsCoaX or BL21 Star(DE3)/pET28a-HpCoaX.  Cultures 
were grown at 37°C to an A600 of ∼0.6, and subsequently induced by the 
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addition of IPTG (a final concentration 800 µM for BsCoaX and 100 µM for 
HpCoaX).  After growing overnight at 37°C, the cells were harvested, 
suspended in sonication buffer (5 mM imidazole, 0.5 M NaCl, and 20 mM Tris-
HCl (pH 7.9), using 10 ml/g cell paste), disrupted by sonication, and 
centrifuged at 15 000 x g for 30 min to clarify the cell-free extract.  The extract 
was applied to a 1 ml HiTrap chelating column and prepared as described by 
the suppliers.  Weakly bound proteins were removed by washing with 
sonication buffer, followed by sonication buffer containing 60 mM imidazole.  
BsCoaX was eluted from the column by using strip buffer (100 mM EDTA, 150 
mM NaCl, 20 mM Tris-HCl pH 7.9).  HpCoaX was eluted by using sonication 
buffer containing 500 mM imidazole.  The purified protein solutions were 
exchanged to gel filtration buffer (5 mM MgCl2, 25 mM Tris pH 8.0 and 5% 
glycerol) using HiTrap desalting columns pre-equilibrated in the same buffer.  
Aliquots of the purified proteins were stored at -80°C.  The concentration of 
the proteins was determined by the Bradford method according to the 
instructions of the supplier. 
SDS-polyacrylamide gels determined the purity of the proteins.  The gels 
consist of a running gel and a stacking gel: 
12% Running gel:  40 % (v/v) 30 % acryl-bisacrylamide mix (Sigma), 
0.75 M Tris pH 8.8, 0.1 % SDS (v/v), 0.1% APS 
(v/v), 0.04 % TEMED (v/v). 
 
Stacking gel: 17% (v/v) 30 % acryl-bisacrylamide mix (Sigma), 
0.063M Tris (pH 8.8), 1 % SDS (v/v), 1 % APS (v/v), 
0.33 % TEMED (v/v). 
A vertical slab gel was cast consisting of a stacking gel and a running gel.  
This was done on a Hoefer Mighty Small II SE 250 assembly (AEC 
Amersham).  All the samples were treated with 2 X loading buffer (0.125 M 
Tris-HCl pH 6.8, 4 % SDS, 30 % glycerol, 1.5 % β-mercaptoethanol and 0.02 
% bromophenol blue).  Thereafter, they were incubated in a heating block at 
95 ˚C for 5 minutes.  The molecular weight marker (Broad Range Protein 
Molecular Weight Marker from Promega) was not heat shocked and loaded as 
Chapter 4:  Characterization of the First Type III Pantothenate Kinase 78 
 
instructed by the supplier.  5 µg of sample protein (we loaded 0.5 µl when 
loading crude extract) was applied to each well.  Electrophoresis was carried 
out in 1 x SDS-PAGE running buffer (10 x buffer consists of 1 % SDS, 0.25 M 
Tris and 1.92 M glycine) at 20 mA until the front of the samples reached the 
bottom of the gel.  The gel was stained for half an hour with coomassie blue 
R-250 staining solution (2.5 % Coomassie brilliant blue R-250, 45 % methanol 
and 10 % acetic acid).  De-staining was carried out in two changes of de-
staining solution (45 % methanol, 10 % acetic acid). 
4.4.5.  Determination of Kinetic Parameters  
Pantothenate kinase activity was measured in a continuous fashion by 
coupling the production of ADP to the reactions catalyzed by pyruvate kinase 
and lactate dehydrogenase, and monitoring the decrease in NADH 
concentration spectrophotometrically at A340 (Figure 4.8).   
All reactions were performed at 25°C.  Kinetic parameters were determined by 
global non-linear fitting of the initial rate data at varying ATP and pantothenate 
concentrations to the general equation for a steady-state bireactant model 
(11): 
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where A is ATP, B is pantothenate, KA and KB are the Michaelis constants for 
ATP and pantothenate respectively and KiA is the enzyme inhibition constant 
for the reverse reaction. 
Each 300 µl reaction mixture contained 100 mM HEPES (pH 7.6), 20 mM KCl, 
10 mM MgCl2, 2 mM PEP, 0.3 mM NADH, 5 U of lactate dehydrogenase, 2.5 
U of pyruvate kinase and 4.5 µg of pantothenate kinase.  ATP concentrations 
were varied between 0.5 and 15 mM and pantothenate concentrations 
between 5 and 500 µM.  Reactions were initiated by the addition of 
pantothenate. 
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Figure 4.8.  Schematic representation of the reactions involved in the pantothenate 
kinase assay.  The ATP-dependent phosphorylation of pantothenate to phosphopantothenate 
produces ADP and uses Mg2+.  The ADP produced is fed into the reaction catalysed by 
pyruvate kinase, which dephosphorylates PEP producing pyruvate.  Finally pyruvate is reduced 
to lactate in a reaction that oxidises NADH.  This oxidation of NADH can be monitored at A340 
and this is how the activity of pantothenate kinase is quantified. 
 
4.4.6.  Inhibition Studies 
Reaction mixtures for inhibition studies were identical to those described 
above except that the pantothenate (500 µM) and ATP (5.0 mM for BsCoaX, 
10.0 mM for HpCoaX and 1.5 mM for E. coli PanK) concentrations were kept 
constant.  Inhibitors (CoA, acetyl-CoA or N5-pantothenamide) were added at 
concentrations between 10 and 500 µM and the reaction was initiated by the 
addition of pantothenate. 
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N5-pantothenamide was also tested as a substrate for BsCoaX, HpCoaX and 
S. aureus PanK.  These reactions were performed as described above but 
pantothenate was substituted with N5-pantothenamide and ATP 
concentrations remained constant at 10.0 mM for HpCoaX and BsCoaX and 
1.5 mM for S. aureus PanK. 
4.4.7.  Testing of Alternate Phosphoryl Donors 
To determine whether other phosphate-containing compounds could 
substitute for ATP in the pantothenate kinase reaction catalyzed by BsCoaX 
and HpCoaX, reaction mixtures containing 50 mM Tris pH 7.6, 20 mM KCl, 10 
mM MgCl2, 5 µg of enzyme, phosphate donor (1.5 mM of either ATP, UTP, 
CTP, GTP, phosphoserine or phosphothreonine or 10 mM of either 
acetylphosphate or carbamoylphosphate) and 500 µM pantothenate were 
incubated at 37ºC for 2 hours.  The reactions were placed at 95ºC for 5 min to 
denature the protein, followed by centrifugation at 13,000 rpm for 5 min.  The 
supernatant was applied to a column of Dowex 50WX8-100 resin and rinsed 
with deionized water.  The solvent was subsequently evaporated from the 
combined eluate in a speed vac concentrator.  The dried samples were 
resuspended in 100 µl of 50% aqueous acetonitrile and analyzed by ESI-MS 
by direct infusion into the instrument at a rate of 20 µl/min.  
Phosphoenolpyruvate was tested as a phosphate donor by the two enzyme 
coupled assay described in 4.4.5.  The exception was that ATP was replaced 
with 1.5 mM PEP, pyruvate kinase was left out and only one pantothenate 
concentration was used, namely 500 µM. 
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 C h a p t e r  5  
Mutation Studies of the Type III Pantothenate 
Kinase from H. pylori 
5.1.  Introduction 
This chapter reviews the literature available to date on the classification of the 
Type I pantothenate kinase into the Rossmann-like fold group of kinases.  In 
addition, we present evidence for the placement of the Type II and III PanKs 
into the ribonuclease H-like family of kinases. By placing these PanKs into this 
fold group certain conclusions can be drawn with regard to their active sites 
when compared to other members of this fold group with solved structures.  In 
particular, amino acid residues within the active site are identified as 
conserved in members of this fold group.  This chapter investigates the 
consequences of mutational studies on these conserved amino acid residues. 
5.2.  Structural Analysis of Kinases  
Kinases are a group of enzymes that catalyze the phosphoryl transfer reaction 
from a phosphate donor (usually ATP) to a receptor substrate (1).  In order to 
investigate the relationship between structural fold and functional 
specifications in all known kinases Cheek et al. (1) carried out a 
comprehensive analysis of all the available kinase structures and sequences.  
These were then classified into structure/sequence families with evolutionary 
implications.  In addition to this they predicted the structures of some kinases 
with unknown structures.  In so doing, possible biochemical roles are 
suggested by the function of these proteins’ homologues (1). 
Chapter 5:  Mutation Studies of the Type III Pantothenate Kinase of H. pylori 85 
 
In order to create this kinase classification the authors constructed a list of all 
the Pfam5 profiles and COGs that describe catalytic kinase domains (2, 3).  
After extensive analysis to remove redundant entries a list containing 57 
kinase profiles was created (44 from Pfam and 12 from COG).  After all the 
kinases sequences were assigned to Pfam/COG profiles or to novel 
groupings, PSI-BLAST6 (4) was used to detect possible evolutionary links 
between the profiles.  Sequences from different Pfam/COG profiles with 
statistically significant similarities were identified and assembled into families.  
In this way, homology is inferred to all sequences in the same family.  The 
authors found that in most cases finding these links was trivial (a trivial link is 
one that is established by three iterations of PSI-BLAST (4) with E-value cut-
off 0.001).  For orphan Pfam/COG profiles or sequence groupings, multiple 
alignments were constructed in order to reveal conserved active-site motifs.  
Secondary structure predictions with Jpred7 (5) and manual inspection of PSI-
BLAST (4) search results were performed.  In some cases, orphan groupings 
could be placed into existing families while in others they had to be assigned 
to novel kinase families.  Only kinases that use ATP as a phosphate donor 
were used as subjects in this study (1). 
A total of 30 kinase families were classified.  Of these kinase families, 19 
contained at least one member with solved structure.  These 19 families could 
be assembled into seven fold groups on the basis of similarities of structural 
fold.  Families in the same fold group share structurally similar nucleotide-
binding domains that are of the same architecture and topography for at least  
                                                 
5 Pfam is a web-based database containing a large collection of protein multiple sequence 
alignments and profile hidden Markov models for finding domains in new sequences.  COG is 
a database of Clusters of Orthologous Groups of proteins.  The function of this database is to 
attempt to phylogenetically classify the proteins encoded by complete genomes.  
6 BLAST is an algorithm that is used to search protein and DNA databases for sequence 
similarities.  PSI in PSI-BLAST stands for Position-specific iterated BLAST and runs at the 
same speed per iteration as gapped BLAST, but in many cases is more sensitive to weak but 
biologically relevant sequence similarities. 
7 Jpred is a server for the prediction of a consensus secondary sequence structure from an 
amino acid sequence. 
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Table 5.1.  Classification of kinase activity by fold group (6). 
the core of the domain.  The remaining ten groups are composed of the 11 
families that contain no members with solved structures (1).  A revision was 
made to this study in 2005 (6) where the number of kinase families was 
reduced to 25, wherein 22 families for which the three-dimensional structures 
are known fall into 10 groups.  In addition, two novel kinase structural folds 
were highlighted bringing the total number of fold groups to 12 (Summarized 
in Table 5.1) (6). 
To summarize, comparative analysis of the protein structural folds allows for 
the inference of biochemical and biological functional properties among 
kinases.  Structure analysis methods are able to detect evolutionary 
relationships that sequence similarity searches miss because protein structure 
conservation persists after sequence similarity disappears.  One must still 
consider however, that similarity of fold alone does not necessarily indicate a 
common ancestor (1).   
Group Examples of Kinase activities 
Group 1: Protein S/T-Y kinase/ 
atypical protein kinase/ 
lipid kinase 
Choline Kinase 
Group 2: Rossmann-like Pantothenate kinase Type I (P-loop kinase family)
Group 3: Ferredoxin-like fold kinases Creatine kinase 
Group 4: Ribonuclease H-like 
Pantothenate kinase Type II 
Pantothenate kinase Type III 
Hexokinase  
Group 5: TIM β/α-barrel kinases Pyruvate Kinase 
Group 6: GHMP kinase  Galactokinase 
Group 7: AIR synthetase like Thiamine-phosphate kinase 
Group 8: Riboflavin kinase Riboflavin kinase 
Group 9: Dihydroxyacetone kinase Glycerone kinase 
Group 10: Putative glycerate kinase Glycerate kinase 
Group 11: Polyphosphate kinase Polyphosphate kinase 
Group 12: Integral membrane kinases Dolichol kinase 
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5.3.  Fold predictions for Type I, II and III Pantothenate 
Kinases 
5.3.1.  Type I PanK 
The crystal structure of the Type I pantothenate kinase identifies it as a 
member of the P-loop kinase family within the Rossmann-like fold group 
(Group 2) of kinases.  The P-loop family constitutes the largest family in the 
Rossmann-like fold group.  This family contains one three-layered (α/β/α) 
domain.  In the majority of the P-loop kinases, the central parallel β-sheet is 
five-stranded with strand order 23145.  Nucleotide binding in this family is 
distinguished by the presence of the conserved Walker A (GXXXXGKT/S) and 
Walker B (ZZZZD, where Z is any hydrophobic residue) motifs (7).  The 
Walker A motif forms a phosphate binding loop (P-loop) and is found in a 
variety of different proteins that bind nucleotides (8).  In this family of kinases, 
the P-loop is located at the end of the first β-strand and includes the first half 
turn of the following α-helix.  The conserved lysine residue of the Walker A 
motif binds to and orientates oxygen atoms of the β- and γ-phosphate groups 
of ATP.  The essential magnesium cation is coordinated directly by the 
hydroxyl group of the conserved threonine/serine of the Walker A motif and 
indirectly by the conserved aspartate residue of the Walker B motif.  The 
Walker A and B motifs are common in proteins that bind nucleotides such as 
pantothenate kinase (9). 
5.3.2.  Type II PanK 
The crystal structure of the eukaryotic pantothenate kinase is unknown.  Due 
to the lack of sequence identity between the prokaryotic (Type I PanK) and 
eukaryotic (Type II PanK) analogues of pantothenate kinase (10) in 
conjunction with dissimilar predicted secondary structure patterns, the Type II 
PanK is predicted to adopt a different fold pattern to its Type I counterpart.   
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Cheek et al. (6) report that standard sequence similarity search methods 
failed to obtain any reasonable structural assignment; however, several fold 
recognition servers strongly suggest that the Type II PanK adopts a 
ribonuclease H-like fold.   
The ribonuclease H-like group contains the ASKHA (acetate and sugar 
kinase/hsc70/actin) superfamily (11).  These structures are characterized by 
the duplicate domains of the ribonuclease H-like fold.  The ribonuclease H-like 
fold is composed of three layers (α/β/α).  The five-stranded mixed β-sheet has 
strand order 32145, with strand 2 antiparallel to the rest of the sheet.  The 
topology of the core of this fold is βββαβαβα.  Nucleotide binding and divalent 
metal coordination are achieved by interactions of the ATP with several motifs 
conserved within the ASKHA superfamily (11).  These conserved motifs 
include the ADENOSINE motif that interacts with ribosyl and the α-phosphoryl 
group of ATP, the PHOSPHATE 1 motif that interacts with the magnesium ion 
through coordinated water molecules, and the PHOSPHATE 2 motif that 
interacts with the β- and γ-phosphoryl groups of ATP.  The mechanism of 
kinases in this group is presumed to be acid-base catalysis.   
Thus, based on the presence of these conserved motifs in addition to the 
similarity of secondary structure patterns (Figure 5.1) within the Type II 
PanKs, they have been classified as a member of the ribonuclease H-like 
family (6).   
5.3.3.  Type III PanK 
In the same way that the Type II panK enzymes were assigned to the 
ribonuclease H-like family (1), so too were the Type III PanKs.  This was 
based on the lack of sequence identity between the Type I and Type III PanKs 
as well as their dissimilar predicted secondary structure.  All the 
characteristics of the ribonuclease H-like fold family can be obtained from 
5.3.2 above. 
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Figure 5.1.  Type II pantothenate kinase is a ribonuclease H-like kinase.  Multiple sequence 
alignment for representative sequences of the pantothenate kinase family and two related 
ribonuclease H-like families with known structure (2-hydroxyglutaryl-CoA dehydratase 
component A (PDB Ihux (12)) and hexokinase I (PDB Idgk (9)) is shown.  Residue conservation 
is denoted with the following scheme: uncharged, highlighted in yellow; charged/polar, 
highlighted in grey; small, red; identical, bold. Dashed boxes indicate the PHOSPHATE 1, 
PHOSPHATE 2 and ADENOSINE motifs.  Abbreviations of species names are as follows: Af 
Acidaminoccus fermentans, At Arabidopsis thaliana, Bc Bacillus cereus, Ca Clostridium 
acetobutylicum, Ce Caenorhabditis elegans, Dm Drosphila melanogaster, En Emericella 
nidulans, Hs Homo sapiens, Mm Mus musculus, Mt Methanothermobacter thermautotrophicus, 
Pa Pichia angusta, Ta Thauera aromatica, and Tt Thermoanaerobacter tengcongensis.  
Locations of predicted (gil4191500) and observed (pdb Ihux_A, PDB Idgk_N) secondary 
structure elements (E, β-strand; H, α-helix) are marked above the sequences in green and blue 
font respectively (6).  Reproduced with permission from Cheek et al. (2005) BMC Structural 
Biology 5, 6. 
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Our collaborators8 have constructed a multiple sequence alignment for 
representatives of the CoaX proteins (Type III), Type II pantothenate kinase 
families as well as members of the ribonuclease H-like fold family with known 
structures.  The conservation of the motifs of the ribonuclease H-like families 
between the CoaX and Type II proteins is noted in Figure 5.2.  This multiple 
sequence alignment helps to identify a number of conserved amino acids 
within the conserved motifs.  Specifically, these alignments identify key 
aspartate residues that are putatively involved in the binding of Mg2+ and the 
stabilization of the phosphate group of ATP during the course of the 
pantothenate kinase reaction, and are based on the known interactions of 
other ribonuclease H-like proteins.  Based on the numbering of the amino 
acids of HpCoaX (line 1 of I in Figure 5.2) it is possible to identify aspartate 
residues number 17 (in PHOSPHATE 1), 87 and 102 (in PHOSPHATE 2) in 
particular as conserved. The following section details a representative of the 
ribonuclease H-like family, hexokinase I.  The purpose of this is to highlight 
the importance of certain amino acid residues in the active site of this protein.  
Based on the importance of these residues in hexokinase I, comparisons will 
be made with the corresponding amino acids within the HpCoaX protein.  
Through mutational studies, we hope to elucidate the importance of these 
corresponding amino acids in the active site of a representative of the Type III 
pantothenate kinases, namely HpCoaX.  This will allow us to ascertain the 
behaviour and interaction between enzyme and substrate.  The information 
gained from these studies will provide insight into the function of the Type III 
pantothenate kinases. 
To summarize, even in the absence of solved structures of either the Type II 
or CoaX-like (Type III) pantothenate kinase proteins it is possible to identify 
key residues through sequence alignments with proteins of known structure.  
These are based on the predicted structural homologies identified in 
                                                 
8 This sequence alignment was compiled by Prof Nick Grishin and Dr Krzysztof Ginalski of the 
Department of Biochemistry, University of Texas Southwestern Medical Centre, USA.  
Together with Prof Hong Zhang, a structural biologist from the same department, they have 
been our key collaborators on the structural aspects of this project.   
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preliminary studies using fold prediction servers (Figure 5.2).  In this chapter, 
extensive mutagenesis studies of the aspartate residues that are conserved 
and predicted to be involved in catalysis will be carried out.   
5.3.4.  Hexokinase I – An Example of a Ribonuclease H-like 
kinase 
Hexokinase I is the pacemaker (9) of glycolysis in brain tissue.  It is composed 
of two structurally similar halves, connected by an α-helix.  Hexokinase I 
catalyzes the phosphorylation of glucose by ATP to produce glucose 6-
phosphate (G6P).  In brain tissue and red blood cells hexokinase I regulates 
glucose metabolism.  When the active site of hexokinase I (H. sapiens, PDB 
code 1dgk) is in the open conformation, productive association with the 
adenine nucleotide takes place (9) (Figure 5.3). 
A loop of amino acids corresponding to residues 532-539 is involved in the 
opening of the active site.  A model has been constructed to explain the 
binding that takes place within the active site (Figure 5.4).  The model for the 
Mg2+-ATP/glucose (Glc) complex of hexokinase I shares features of metal-
ATP complexes of related enzymes (glycerol kinase, actin and hsp70).  
Thr863 of the ADENOSINE motif (11) interacts with the ribosyl and α-
phosphoryl groups of ATP, Asp532 (PHOSPHATE I motif, corresponds to 
Asp17 in HpCoaX) interacts with the Mg2+ through coordinated water 
molecules, and loop 679-681 (PHOSPHATE II motif, this region corresponds 
to the region housing Asp102 in HpCoaX) has conserved interactions with the 
β and γ-phosphoryl groups of ATP. 
Asp657 (corresponds to Asp87 in HpCoaX) hydrogen bonds with the 6-
hydroxyl group of glucose as a proton acceptor, and is a putative catalytic 
base.  The mutation of Asp657 to alanine reduces the kcat by at least 100 fold 
(13).  Clearly, these amino acid residues (mentioned above) within the active 
site of this protein are important to the activity of the enzyme.  By comparing 
the active site of hexokinase, an example of a ribonuclease H-like kinase with 
a solved structure, with that of the HpCoaX active site we were able to identify 
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Asp residues within the HpCoaX active site that we suspected of being 
involved in catalysis.  Mutation of these aspartate residues would enable us to 
ascertain their relevance in the active site of HpCoaX and infer this 
importance to other as yet unclassified homologues of the HpCoaX protein. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  The ADP/Glc complex of hexokinase.  The large domain of Hexokinase is light 
purple and the small domain yellow.  Dotted red lines indicate donor-acceptor interactions.  The 
β-phosphoryl group of ADP is not productively bound in the ADP/Glc monomer complex due to 
the steric influence of loop 532-539.  In the conformation observed for the open C-half (green), 
however, loop 532-539 allows productive binding of the β and γ-phosphoryl groups of ATP 
(black lines) with Mg2+ (black sphere) (9).  (Figure reproduced with permission from Elsevier, J. 
Mol. Biol., 296, Aleshin et al., Crystal Structures of Mutant Monomeric Hexokinase I Reveal 
Multiple ADP Binding Sites and Conformational Changes Relevant to Allosteric Regulation, 
1001-1015, (2000)). 
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Figure 5.4.  Stereoview of the Mg2+-ATP/Glc complex of the active site of hexokinase I.  
The illustration is based on a model derived from the ADP/Glc monomer complex of Hexokinase 
I.  Structural elements in purple and yellow are from the large and small domains, respectively, 
of the C-terminal half of Hexokinase I.  Elements in green represent loop 532-539 in its open 
conformation.  Dotted red lines designate donor-acceptor interactions.  Mg2+ and its coordinate 
bonds are black, with four red spheres representing coordinated water molecules.  The 6-
hydroxyl group of Glc is in line with respect to the γ-phosphoryl group of ATP, with Asp657 
acting as a catalytic base (9).  (Figure reproduced with permission from Elsevier from Aleshin et 
al. (2000) Crystal Structures of Mutant Monomeric Hexokinase I Reveal Multiple ADP Binding 
Sites and Conformational Changes Relevant to Allosteric Regulation, J. Mol. Biol., 296, 1001-
1015). 
5.4.  Results and Discussion 
5.4.1.  Critical Residues Involved in Enzyme Activity 
Although their properties are very different, the Type II and III PanK’s are 
predicted to belong to the same fold group, namely the ribonuclease H-like 
fold group.  Sequence alignments were performed between representatives of 
the CoaX Type III pantothenate kinases, their Type II counterparts and 
proteins belonging to the same fold superfamily with known structures.  The 
resulting sequence alignment (Figure 5.2) identifies a number of aspartate 
residues that are highly conserved in many of sequences compared.  
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Aspartate residues corresponding to H. pylori (Line 1 of group I in Figure 5.2) 
amino acid residues number 17, 87 and 102 are highly conserved and 
possibly involved in catalysis. 
5.4.2.  Mutational Analysis 
As stated above, three aspartate residues were identified for mutation studies.  
These aspartate residues were mutated to both asparagine and glutamate 
(Figure 5.5).   
 
 
 
Figure 5.5.  A comparison of the structures of asparagine, aspartate and glutamate.  The 
side chains of the amino acids are coloured in blue (14).  
Mutation from aspartate to asparagine is experimentally meaningful as these 
two amino acids are identical except that in asparagine, an amide group 
replaces the γ-carboxyl group of aspartate and results in the side chain being 
polar but uncharged.  In contrast, aspartate is negatively charged at 
physiological pH.  This change clearly has repercussions with regard to the 
chemical property of the side chain and therefore could influence the activity 
of the protein if the selected amino acids are involved in catalysis.  If the net 
negative charge was the pre-requisite for enzyme action then making this 
change should seriously hamper enzyme activity.  Negatively charged amino 
acids play several roles in proteins.  For example, proteins that bind metal 
ions (like PanK) often possess metal binding sites containing one or more 
aspartate or glutamate residues.  Thus, by making this change we are probing 
for the importance of the ionic nature of the aspartate residue in question. 
Mutation from aspartate to glutamate retains the acidic nature of the amino 
acid side chain but increases the tether length by one methylene group 
(Figure 5.6).  Glutamate, like aspartate, is also negatively charged at 
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physiological pH.  Thus by making this change we are probing for the 
importance of the negative charge at exactly the right position within the active 
site.  The binding pockets of most proteins are highly specific and uniquely 
designed to accommodate and bind their substrates.  Any interference in the 
spatial arrangement of the substrates in the active site could hamper the 
activity of the enzyme in question.   
Figure 5.6.  A rudimentary diagram of the interaction between an aspartate side chain 
(left) and glutamate side chain (right) and the γ-phosphoryl of ATP, facilitated by a 
magnesium ion.  Because of the additional methylene group in glutamate (highlighted in red), 
the distance between the amino acid and the ATP molecule is shorter, while in the case of 
aspartate (highlighted in blue) the distance is longer.  This could cause a small measure of 
steric hindrance in the active site of the enzyme and explain why, in the case of pantothenate 
kinase, aspartate is the acidic amino acid of choice. 
Thus, the increased tether length of the side chain of glutamate could have 
spatial implications in the active site of the protein.  Consider Figure 5.6 
above, where one can see that replacing an aspartate residue with a 
glutamate residue increases the space required in the binding pocket of the 
enzyme.  While this is a miniscule difference, the architecture of enzymology 
is so acutely specific that perhaps the addition of just a single methylene 
group in the side chain required to bind the magnesium ion could hamper 
enzyme activity. 
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5.4.3. Purification of Mutant Proteins 
Mutagenesis PCR was conducted on the original overexpression vector 
(pET28a-HpCoaX) containing the H. pylori coaX gene insert.  The 
mutagenesis PCR reactions changed the residues Asp17, Asp87 and Asp102 
to either asparagine or glutamate.   
The success of the mutagenesis reactions was confirmed by automated DNA 
sequencing.  In the case of the mutation of residues 17 and 87 from aspartate 
to glutamate we experienced difficulties with the above procedure.  As the 
asparagine mutants had already been cloned and verified by automated 
sequencing at this point, we used these plasmids as templates for the 
mutational PCR reaction.  This proved successful for both of the outstanding 
mutants. 
The mutant plasmids were transformed into E. coli BL21 Star(DE3) and the 
proteins overexpressed and purified using immobilized metal affinity 
chromatography.  The purity of the mutant proteins in relation to native 
HpCoaX is depicted in Figure 5.7.  For one protein, namely HpCoaX(D17E), 
expression conditions could not be created where the protein expressed 
successfully.  The presence of the mutated gene was verified through 
sequencing, but under no conditions was there protein present in the crude 
extract.  We investigated the possibility that the replacement of the aspartate 
with a glutamate residue resulted in the introduction of a protease site.  
However, this was not the case in our E. coli expression system.  Other 
possibilities for the lack of expression include instability of the protein, the 
formation of inclusion bodies after expression or degradation of the protein 
after expression.  These factors have to be investigated further as we would 
like to be able to include this protein in our mutant analysis.  Whatever the 
cause of the lack of expression may be, this protein was not purified and thus 
was not part of our study as initially planned.  The purity of the remaining 
mutants as compared to native protein is illustrated in the SDS-PAGE gel 
depicted by Figure 5.7.   
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Figure 5.7.  SDS-PAGE analysis of the purity of the HpCoaX mutants as compared to 
native protein.  Lane 1: Molecular weight markers (kDa).  Lane 2: native HpCoaX. Lane 3: 
HpCoaX(D17N).  Lane 4: HpCoaX(D87N).  Lane 5: HpCoaX(D87E).  Lane 6: HpCoaX(D102N) 
and Lane 7: HpCoaX(D102E). 
5.4.4.  Activity of CoaX Mutants 
The purified proteins were assayed for their ability to catalyze the ATP-
dependent phosphorylation of pantothenate using the same two enzyme-
coupled assay that links the production of ADP to the oxidation of NADH. This 
allows the enzyme activity to be measured continuously by monitoring the 
change in A340. We chose a final ATP concentration of 15 mM and the 
reactions were initiated by the addition of 500 µM pantothenate.   
The results indicate that when compared to native protein activity, mutation of 
the aspartate residue (to either asparagine or glutamate) at any of the three 
sites seriously hampers the activity of the protein (Table 5.2 and Figure 5.8).   
One would expect to see a marked decrease in activity when an aspartate is 
mutated to an asparagine if the negative charge on the γ-carbonyl of 
aspartate is required for metal binding and catalysis, while a decrease in 
activity in the case of the glutamate mutants would indicate the importance of 
the location of the negative charge in the active site.   
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Table 5.2.  Rate and percentage remaining activity of mutants compared to native 
HpCoaX. 
Hp variant Activity (nmoles.sec-1.µg-1) 
% Relative 
remaining 
activity 
HpCoaX 0.035 100 
HpCoaX(D17N) 0.000 0 
HpCoaX(D87N) 0.011 32 
HpCoaX(D87E) 0.012 35 
HpCoaX(D102N) 0.010 28 
HpCoaX(D102E) 0.015 43 
Figure 5.8.  The percentage remaining activity of mutant CoaX proteins compared to that 
of the native CoaX protein.  None of the mutated proteins maintains even 50 % of the activity 
of the native protein.  In fact, mutation at aspartate residue 17 completely abolishes enzyme 
activity. 
We found that the proteins where the aspartate residues were mutated to 
asparagine show a greater decrease in activity when compared to the same 
residues mutated to glutamate (32 % for HpCoaX(D87N) as compared to 35 
% for HpCoaX(D87E) and 27 % for HpCoaX(D102N) as compared to 42 % for 
HpCoaX(D102E).  However, mutations to glutamate were still far less active 
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than the native protein.  This supports the suggestion that the absolute 
position of these aspartate residues at the chosen sites also plays a role in the 
optimum function of the HpCoaX enzyme.  The differences in remaining 
activity between asparagine and glutamate mutations at any one site were not 
at all significant suggesting that changing the charge or the position of the 
negative charge of the amino acid side chain was sufficient to decrease 
activity of the HpCoaX protein by more than 50 %. 
In particular, mutation of the aspartate residue at position 17 to asparagine 
completely abolishes protein activity.  This aspartate residue is clearly 
essential to enzyme function.  This aspartate residue is predicted, like Asp 
532 in hexokinase I, to interact with the Mg2+ through coordinated water 
molecules.  Magnesium is a vital metal cofactor for the activity of pantothenate 
kinase and it comes as no surprise that blocking its interaction with the active 
site abolishes enzyme activity.   
According to Figure 5.2 the amino acid at the position corresponding to H. 
pylori Asp87 is glutamate in all but one of the kinases with known structure.  In 
the case of hexokinase I (subheading 5.4) mutation of this glutamate residue 
reduced the kcat of the enzyme 100 fold (9).  This residue in hexokinase I is a 
suspected catalytic base.  It is possible that the corresponding aspartate in 
HpCoaX (Asp 87) has a similar function.  Whatever the case may be mutation 
of this residue to either glutamate or asparagine decreases the activity of the 
enzyme dramatically.  This could be due to the lack of charge of the 
asparagine mutant or the incorrect placement of the charge of the glutamate 
mutant.   
The smallest difference in remaining activity is present in the mutations at 
aspartate position 87, with HpCoaX(D87N) having a remaining activity of 32 % 
as a compared to 35 % remaining activity for HpCoaX(D87E).  In hexokinase 
I, the corresponding amino acid (Asp657) is involved with binding of glucose, 
the enzymes’ main substrate (13).  However, it is not the only amino acid 
residue that is involved in this function.  It is possible that the same is true for 
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Asp87 in HpCoaX and mutating this residue alone is not enough to abolish 
this function of the enzyme. 
Aspartate residue 102 is putatively involved in phosphate binding (Figure 5.2).  
Hexokinase I does not have an aspartate residue at this corresponding site, 
instead it has an isoleucine (non-polar/hydrophobic) (6, 14).  The loop of 
residues from 679-681 containing this isoleucine make up part of the 
PHOSPHATE II motif.  This motif is responsible for the conserved interactions 
between the β and γ-phosphoryl groups of ATP.  All the other kinases in the 
group with known structure have an aspartate at this position.  As a result of 
the implied structural homology, we can conclude that Asp102 of HpCoaX is 
also involved with phosphate binding.  Asparagine cannot perform this 
function and that may be why its activity is lower than that of the same 
glutamate mutant.  It is possible that steric hindrance is the reason that the 
glutamate residue is not as successful in this role as the native aspartate.  
Because of the presence of another aspartate residue involved in phosphate 
binding (Asp17 in PHOSPHATE I), mutation of just the single residue at 
Asp102 (PHOSPHATE II) may not be enough to abolish activity.  It appears 
that the level of importance of phosphoryl binding is not equal between the 
two residue positions.  Mutation of the aspartate at residue 17 completely 
abolishes activity, while mutation of the aspartate residue at position 102 
simply lowers activity.  This points to a hierarchy, where Asp17 is more 
important than Asp102 in phosphoryl binding. 
Taken together, the results indicate that all three of the residues chosen for 
mutation are involved in the functionality of HpCoaX.  This is evidenced by the 
fact that a mutation at any one of these residues causes a decrease of activity 
of more than 50 %. 
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5.5.  Conclusion 
By comparison to proteins within the ribonulcease H-like family we were able 
to identify the presence of conserved aspartate residues within the active site 
of H. pylori PanK.  Aspartate residues numbers 17, 87 and 102 in H. pylori 
were mutated to both asparagine and glutamate.  We expected residual 
activity to remain in the glutamate mutants as both aspartate and glutamate 
are acidic amino acids and have a very similar structure.  However, even in 
the case of the two glutamate mutants (D87E and D102E), activity was 
significantly reduced.  This is explained by the fact that glutamate has an 
additional methylene group and does not comply with the spatial constraints of 
the active site and thus cannot bind substrate as efficiently as aspartate can.  
The total eradication of activity caused by mutation of Asp residue 17 implies 
the absolute necessity of an aspartate residue at this position in the active site 
of HpCoaX. 
As predicted, mutation to asparagine at the identified aspartate sites 
decreased the activity of the enzyme further.  In fact, mutation of aspartate 
residue number 17 to asparagine completely abolishes enzyme activity.  The 
effect of mutating Asp102 to asparagine also had a more pronounced effect 
than the same mutation to glutamate.  This aspartate residue is predicted to 
be involved in interactions with the β and γ-phosphoryl groups of ATP.  
Mutation of this residue to asparagine decreases the activity of the protein.  
This means that even though the binding of the phosphates of ATP to the 
enzyme is impaired it is not abolished and the phosphorylation of 
pantothenate can still take place, albeit more weakly. 
It is unclear what the exact function of aspartate residue number 87 is.  It is 
possible that, like its counterpart in Hexokinase I, it is involved in the binding 
of its main substrate, namely pantothenate.  It clearly does have some 
relevant function as mutation of this residue seriously hampers the function of 
the protein.  This mutant showed the highest of levels of remaining activity in 
both the asparagine and glutamate mutants.  This is surprising as the majority 
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of residues corresponding to this one in group II and III (Figure 5.2) are 
naturally glutamate residues.  All the corresponding amino acids in the CoaX 
like group (group I Figure 5.2) are aspartates.  It is possible that this is a key 
difference in the structure of the pathogenic bacteria as compared with the 
other, mainly eukaryotic pantothenate kinases, belonging to the ribonuclease 
H-like group of proteins. 
These mutation studies indicate that the placement of the Type III PanKs into 
the ribonuclease H-like fold family is justified.  This is supported by the fact 
that the mutation of conserved amino acids identified by sequence homology 
impairs the activity of the resulting proteins. 
5.6.  Methods and Materials 
5.6.1.  Materials 
All chemicals were purchased from Aldrich, Sigma or Fluka and were of the 
highest purity. Other materials were from the following suppliers: Pyruvate 
kinase and lactate dehydrogenase enzymes from Roche; restriction 
endonucleases and Pfu DNA polymerase from Fermentas; Bradford dye 
reagent from Biorad; oligonucleotides from Inqaba Biotechnology (Pretoria, 
South Africa); and HiTrap columns from Supelco.  Automated DNA 
sequencing was performed by Inqaba Biotechnology (Pretoria, South Africa). 
Proteins were purified on an ÄKTA Prime instrument (Amersham 
Biosciences). Enzyme assays were performed on a Multiskan Spectrum 
multiplate spectrophotometer (ThermoLabsystems), using an extinction 
coefficient of 6220 M-1.cm-1 for NADH.  
5.6.2.  Mutant Construction 
The coaX gene in plasmid pET28a encoding the wild type H. pylori CoaX 
protein was mutated by PCR to introduce the mutations at aspartate positions 
17, 87 and 102 in the protein sequence.  The pET28a-HpCoaX plasmid 
cloned in section 4.4.2 was used as template for the PCR reactions except for 
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the PCR reactions creating the mutants D17E and D87E, where the plasmids 
pET28a-HpCoaX(D17N) and pET28a-HpCoaX(D87N) respectively, were used 
as templates.  The primers for the above PCR reactions were as follows: 
D17N: 
Forward Primer:  5’-TTTGAAAAACCTGGTTTTATGCAATATAGGTAATACGCGCATCC-‘3 
Reverse Primer:  5’-GGATGCGCGTATTACCTATATTGCATAAAACCAGGTTTTTCAAA-‘3 
D17E: 
Forward Primer:  5’-AACCTGGTTTTATGCGAGATAGGTAATACGCGCATC-‘3 
Reverse Primer:  5’-TGCGCGTATTACCTATCTCGCATAAAACCAGGTT-‘3 
D87N: 
Forward Primer:  5’-GGGCTTGGGATAAACCGGCAAATGGCGTG-‘3 
Reverse Primer:  5’-GCCATTTGCCGGTTTATCCCAAGCCCTAC-‘3 
D87E: 
Forward Primer:  5’-TTGGGATAGAGCGGCAAATGGCGTG-‘3 
Reverse Primer:  5’-GCCATTTGCCGCTCTATCCCAAGCC-‘3 
D102N: 
Forward Primer:  5’-GTGGTGGTGAATTCGGGGAGCGCGA-‘3 
Reverse Primer:  5’-CGCTCCCCGAATTCACCACCACGCC-‘3 
D102E: 
Forward Primer:  5’-GTGGTGGAGGCGGGGAGCGCG-‘3 
Reverse Primer:  5’-GCTCCCCGCCTCCACCACCAC-‘3 
 
The resulting expression vectors were named pET28a-HpCoaX(D17N), 
pET28a-HpCoaX(D17E), pET28a-HpCoaX(D87N), pET28a-HpCoaX(D87E), 
pET28a-HpCoaX(D102N) and pET28a-HpCoaX(D102E). 
5.6.3.  Protein Purification 
The pET28a-HpCoaX mutants were transformed into E. coli BL21 Star(DE3) 
(Invitrogen) and overnight cultures (500 µl) of these transformants were used 
to inoculate LB media (500 ml) supplemented with 30µg/ml kanamycin sulfate.  
Cultures were grown at 37°C to an A600 of ∼0.6 and subsequently induced by 
the addition of 100 µM IPTG.  After growing overnight at 37°C and shaking at 
200 rpm, the cells were harvested by centrifugation, suspended in sonication 
buffer (5 mM imidazole, 0.5 M NaCl, and 20 mM Tris-HCl (pH 7.9), using 10 
ml/g cell paste), disrupted by sonication, and centrifuged at 15 000 x g for 30 
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min to clarify the cell-free extract. The extract was applied to a 1 ml HiTrap 
chelating column prepared as described by the suppliers. Weakly bound 
proteins were removed by washing with sonication buffer, followed by 
sonication buffer containing 60 mM imidazole.  Protein was eluted by using 
sonication buffer containing 500 mM imidazole.  The purified protein solutions 
were exchanged to gel filtration buffer (5 mM MgCl2, 25 mM Tris pH 8.0 and 
5% glycerol) using HiTrap desalting columns pre-equilibrated in the same 
buffer.  The protein concentration was determined by the Bradford method 
using bovine serum albumin as standard.  Aliquots of the purified proteins 
were stored at -80°C.  SDS-PAGE gel analysis was conduced as described 
section 4.4.4. 
5.6.4.  Pantothenate Kinase Assays 
Pantothenate kinase activity was measured in a continuous fashion by 
coupling the production of ADP to the reactions catalyzed by pyruvate kinase 
and lactate dehydrogenase, and monitoring the decrease in NADH 
concentration spectrophotometrically at A340. All reactions were performed at 
25°C. 
Each 300 µl reaction mixture contained 100 mM HEPES (pH 7.6), 20 mM KCl, 
10 mM MgCl2, 2 mM PEP, 0.3 mM NADH, 5 U of lactate dehydrogenase, 2.5 
U of pyruvate kinase 15 mM ATP and 4.5 µg of mutant pantothenate kinase.  
Reactions were initiated by the addition of 500 µM pantothenate. 
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 C h a p t e r  6  
Concluding Remarks and Future Research 
Possibilities 
6.1.  Summary of Findings 
Pantothenate kinase (PanK) catalyzes the first step in the biosynthesis of the 
essential and ubiquitous cofactor coenzyme A (CoA) in all organisms.  Two 
well-characterized analogues of the enzyme are known: Type I, a prokaryotic 
PanK, exemplified by the enzyme from E. coli, and Type II, a eukaryotic 
analogue that has primarily been characterized from mammalian sources. 
Curiously, the genomes of certain pathogenic bacteria, including H. pylori and 
P. aeruginosa, do not contain a pantothenate kinase similar to either 
analogue, although these organisms possess all the other biosynthetic 
machinery required for CoA production.  In this study we cloned, 
overexpressed and characterized an enzyme from B. subtilis as well as its 
homologue from H. pylori and show that they catalyze the ATP-dependent 
phosphorylation of pantothenate.  However, the enzymes do not share 
sequence homology with any known PanK, and neither CoA nor acetyl-CoA 
inhibits their activity.  This stands in contrast with the bacterial and eukaryotic 
PanK analogues which both share a common mechanism of feedback 
regulation by CoA and its thioesters.  The B. subtilis and H. pylori enzymes 
also do not accept the pantothenic acid antimetabolite N-
pentylpantothenamide as a substrate, nor are inhibited by it, which also 
distinguishes them from the atypical S. aureus enzyme that has been 
characterized recently.  Taken together, these results point to the identification 
of a third distinct analogue of PanK that accounts for the only known 
pantothenate kinase activity in pathogens such as H. pylori and P. 
aeruginosa.   
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The Type III pantothenate kinase has unusually high KM values for ATP.  
Other possible phosphate donors were tested and although some measure of 
activity was detected with CTP and GTP none of the donors tested could 
substitute for ATP. 
Aspartate residues involved in catalysis were identified and mutational studies 
indicate that these residues are critical for the complete functionality of the 
protein.  Mutation to glutamate allows residual activity to remain whereas the 
same mutation to asparagine causes the activity of the protein to decrease 
further.  Increasing the substrate concentration does not affect the activity of 
the mutant proteins.  
6.2.  Future Research Possibilities 
6.2.1.  High KM of Type III PanKs 
The CoaX enzymes exhibit a very low specificity for ATP.  This is due to their 
surprisingly high KM values, which is nearly 10 mM in the case of HpCoaX. 
Such large KM values can be rationalized in the case of the BsCoaX enzyme 
that duplicates an activity already embodied by the more typical B. subtilis 
Type I PanK.  However, since H. pylori depends exclusively on HpCoaX for its 
CoA biosynthetic needs, the question arises whether the enzyme’s low 
specificity constant for ATP affects the flux through the pathway.  Further 
studies are currently underway to address this question (1). 
6.2.2.  Finding Inhibitors for Type III PanK 
The Type III pantothenate kinase is refractory to inhibition by CoA or its 
thioesters (1).  This is one of the main differences between it and the other 
pantothenate kinase analogues classified to date.  The only other PanK that 
shows similar lack of inhibition is that of the recently classified S. aureus (2).   
There is currently a paper in press (3) that concentrates on the synthesis of 
inhibitors of the pantothenate kinase enzyme.  The authors synthesized three 
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series of novel pantothenamide-type analogues based on the known S. 
aureus PanK inhibitors, N-pentyl-, and N-heptylpantothenamide.  The first 
series of analogues were designed as molecular probes of the PanK binding 
site.  The reason for this was to elucidate the important structure-activity 
relationships (SAR) within the binding site.  The second set of analogues was 
designed using structural information obtained from the E. coli PanK structure 
by targeting the pantothenate binding site and the adjacent phenylalanine-
lined lipophilic binding pocket.  The construction of the third series of 
analogues was driven by the antimicrobial effect of N-pentylpantothenamide 
(N5-Pan).  The inhibitory effect of this inhibitor is primarily through its 
conversion to the anti-metabolite ethyldethia-CoA and its further incorporation 
into an inactive from of the acyl carrier protein.  Each of the inhibitors 
designed was tested on a number of pantothenate kinase analogues including 
E. coli PanK, S. aureus PanK, Aspergillus nidulans PanK and the murine 
analogue MmPanK1α (3).   
Series one demonstrated only modest inhibitory activity, but revealed some 
relevant structure-activity relationship findings, including stereospecific 
binding.  Series two demonstrated a much higher degree of inhibition for all 
the PanK analogues tested and the authors reported significant inhibition for 
analogues containing alkyl substituents.  Series three exhibited the most 
preferential inhibition profile with the highest degree of inhibition in S. aureus 
PanK and MmPanK1α.  The results indicate that the MmPanK1α is highly 
promiscuous in terms of its inhibitors whereas E. coli PanK shows far greater 
selectivity (3).  This means that selectivity will be a challenge when 
discovering potent inhibitors directed solely at the bacterial enzyme (3).   
These researchers measured the efficiency of inhibitors based on the 
decrease in product (phosphopantothenate) formation.  However, if the 
inhibitors could in fact be phosphorylated by pantothenate kinase then the 
formation of product would be reduced without the enzyme being inhibited.  
This highlights the difference between the inhibition of product formation (i.e. 
competitive substrates) and enzyme inhibition (3).   
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The assay that the authors used to test for inhibition of pantothenate kinase 
activity was a radioactive assay that used radiolabelled pantothenate and 
tested for the presence of radiolabelled phosphopantothenate (3).  This assay 
does not take into account the possibility that PanK may phosphorylate the 
inhibitors themselves as alternate substrates.  This is indeed the case with 
N5-Pan, which is an alternate substrate for the PanK reaction and which is 
eventually transformed by the CoA biosynthetic enzymes to the CoA analogue 
ethyldethia-CoA.  This is the template antimicrobial agent that the authors 
based their inhibitor design on.  Nevertheless, the research is valuable insofar 
as the synthesis of new inhibitors and we would like to conduct a similar study 
taking into account the possibility of the inhibitors being competitive substrates 
for the PanK enzymes.  As of yet, no inhibitors have been found for the Type 
III pantothenate kinases.  As many of members belonging to this group are 
pathogenic bacteria and have no alternative pantothenate kinase enzyme in 
their genomes, finding an inhibitor that specifically targets this group and not 
other analogues of pantothenate kinase would be invaluable to the 
formulation of new drugs against pathogenic bacteria.  The increasing 
bacterial resistance to commonly used antibiotics is of growing concern to the 
healthcare industry.  The development and design of new inhibitors would go 
a long way in developing a means to overcome this dilemma. 
6.2.3.  Alternate Metal Ions Used by Type III PanK 
Our assay for measuring the activity of the Type III PanK relies on its ability to 
catalyze the ATP-dependent phosphorylation of pantothenate using a two 
enzyme-coupled assay (lactate dehydrogenase and pyruvate kinase) that 
links the production of ADP to the oxidation of NADH. This allows the enzyme 
activity to be measured continuously by monitoring the change in A340.  The 
norm is to use magnesium ions in the buffer when monitoring this reaction.  
Mg2+ is an important metal cofactor in the phosphorylation reaction whereby 
pantothenate is phosphorylated to phosphopantothenate by pantothenate 
kinase and ATP.  Due to the very high KM values for the CoaX enzymes we 
postulated that this unique enzyme might use a metal ion other than 
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magnesium.  We would like to explore this possibility.  However, we cannot 
use our current assay system as we would be using different metal ions and 
pyruvate kinase uses Mg2+ exclusively  We will have to adopt an alternative 
assay in order to follow the reactions with other metal ions.  
Jackowski (4), who is very well known for her work on the prokaryotic and 
eukaryotic PanKs, has always used a radioactive assay for monitoring the 
pantothenate kinase reaction.  In this method, pantothenate is radiolabelled 
and the quantity of radioactive phosphopantothenate (product) formed in the 
reaction is measured.  This method of assaying the activity of the enzyme is 
highly accurate and reliable.  Reactions testing the efficiency of alternative 
metal ions in A. nidulans have been conducted by Calder et al. (5) using this 
assay.  Here, magnesium was replaced with calcium, cobalt, manganese or 
zinc.  The authors measured the activity of the enzymes in the presence of 
these metal ions as a function of the activity of the reaction with magnesium.  
Every alternative metal ion resulted in a decrease in the activity as compared 
to the activity obtained with magnesium.  Zinc and calcium in particular 
rendered the enzyme almost inactive with percentages of remaining activity 
less than 3 %.  Manganese and cobalt were able to maintain a certain amount 
of activity, however, neither enabled the enzyme to function above 50 % of its 
normal activity with the magnesium cation (5).   
The results indicate that magnesium is the cation of choice for A. nidulans.  A. 
nidulans PanK belongs to the Type II pantothenate kinases.  Type II and III 
PanKs are expected to have a similar fold structure and thus functional 
domains, one of which is involved with magnesium and phosphoryl binding 
specifically.  This being the case, it seems unlikely that CoaX (Type III) will 
use an alternative cation.  However, it is worth exploring and we will conduct 
experiments to test whether magnesium is the cation of choice for the CoaX 
proteins. 
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6.2.4.  Crystal structure of the Type III PanK 
Complete characterization of the novel CoaX-like pantothenate kinase would 
rely on the elucidation of the crystal structure of the protein.  The crystal 
structure of CoaX with substrates and inhibitors bound would create an even 
clearer picture.  Our collaborators are currently undertaking to solve the 
crystal structure of one of the CoaX proteins. 
Initial studies aimed at determining the structure of the HpCoaX protein failed 
due to the production of low diffraction quality crystals.  As a result of this we 
revisited our sequence alignments for the CoaX-like proteins (see Table I in 
Chapter 3).  We decided to clone the coaX genes from three additional 
putative Type III PanKs, namely, Thermus thermophilus, Treponema pallidum 
and P. aeruginosa.  Having cloned and determined the expression conditions 
for these proteins successfully, the plasmids were sent to our collaborators 
who are currently busy with the structural analysis. 
One of the aims of this collaboration is to compare the CoaX protein to its 
Type I counterparts in regards to structure and mechanism.  We would like to 
elucidate the mechanistic implications of the diverse PanK structures in 
regards to phosphate transfer and the binding of inhibitors of the enzyme.  
Our collaboration will not only expand our understanding of the role of small 
metabolite kinases in central metabolism, but it will also provide for the 
characterization of an analogue of the PanK enzyme that is structurally and 
mechanistically distinct from the known PanK analogues. 
6.2.5.  Cloning and Characterization of Additional Type III 
PanKs. 
As mentioned in the section above we have cloned additional PanKs with 
predicted Type III structure.  Cloning and characterization of these CoaX-like 
proteins will further broaden our understanding of this new analogue of 
pantothenate kinase.  We can compare the results obtained from H. pylori 
with these new members of the Type III PanK family.  Will these PanKs also 
be refractory to product inhibition; will they also show a high KM for ATP?  This 
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could lead to a better understanding of the high KM value recorded for 
HpCoaX.  The more test subjects we have, the more likely it will be that we 
can draw reliable conclusions about the characteristics of the Type III PanK.  
The additional three organisms are all interesting in their own right: 
Thermus thermophilus 
Thermus thermophilus is an extremely thermophilic, halotolerant bacterium 
that was originally isolated from a natural thermal environment in Japan.  The 
organism has considerable biotechnological potential; many thermostable 
proteins isolated from members of the genus Thermus are indispensable in 
research and in industrial applications.  The reason for this is the genus’ high 
maximum growth temperature of 85 °C.  They show high transformation 
competence and are therefore amenable to genetic manipulation.  One 
particular point of interest is that because of its thermostability, it can produce 
proteins that will make ideal candidates for use as biocatalysts.  This would be 
particularly interesting if one were to create a system whereby CoA could be 
produced on an industrial scale.  As a predicted member of the Type III PanKs 
this enzyme is not inhibited by CoA.  This is an additional advantage since this 
would provide an organism that can potentially withstand high temperatures 
and be refractory to feedback regulation by CoA.  This enzyme could be a 
candidate (along with CoaBCDE) for the “one pot” enzymatic biosynthesis of 
CoA. 
Treponema pallidum 
Treponema pallidum is the causative agent of the sexually transmitted 
disease syphilis.  It is a Gram-negative spirochete that is an obligate human 
parasite.  The organism is microaerophilic and requires low concentrations of 
oxygen.  Although the organism initially causes an ulcer at the site of infection, 
over time it can move throughout the body and cause wide spread damage to 
the vital organs.  Usually the disease is treated with penicillin or tetracycline 
(6).  The dose of antibiotic administered depends on the stage of syphilis.  
There is no vaccine against this bacterium.   
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Because of this organisms’ importance as a human pathogen, it would make a 
very interesting test species.  We would not have to physically culture the 
bacteria and all expression work would be conducted in E. coli.  For this 
reason, we can gain a great deal of insight into an organism that threatens 
thousands of people, while maintaining a high level of security.  Specifically, if 
this organism has a CoaX-like PanK, it would be very interesting for the 
testing of novel inhibitors.  A recent publication has identified the penicillin 
binding protein (named Tp47) in T. pallidum.  In this study the authors 
concluding remarks indicate their fear that a mutation of this protein would 
lead to the resistance of the bacterium to the administration of penicillin (6).  
This means that like so many diseases, our current means of treatment would 
no longer be effective.  This lends additional impetus to the design of novel 
inhibitors for the CoaX enzymes (as discussed in 6.3) above. 
Of special interest is the fact that this organism does not have the coaBC 
gene.  CoaBC encodes a flavin mononucleotide (FMN)-containing bifunctional 
enzyme responsible for both the 4’-phosphopantotheinoylcysteine synthetase 
and the 4’-phosphopantotheinoylcysteine decarboxylase activities (7, 8) in 
coenzyme A biosynthesis. It is possible that this enzyme uses pantetheine as 
a starting substrate for CoA biosynthesis instead of pantothenate and uses 
the enzyme CoaD to process this further to CoA.  We would like to explore 
this possibility experimentally. 
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Figure 6.1.  A comparison of the CoA biosynthetic pathway between Escherichia coli (A) 
and Treponema pallidum (B).  Note that E. coli is capable of pantothenate biosynthesis, 
whereas T. pallidum is not.  In addition to this, T. pallidum does not have the gene encoding for 
the protein CoaBC (genes absent from the organism are unshaded and those present are 
shaded in green).  This means that this organism cannot catalyze the reaction converting 4’-
phosphopantothenate to 4’-phosphopantetheine.  It does, however, have the gene responsible 
for encoding the CoaD protein that converts 4’-phosphopantetheine into dephospho-CoA.  It is 
plausible then that T. pallidum is capable of CoA biosynthesis with pantetheine as starting 
product.  Reproduced from http://www.genome.jp/kegg/pathway.html 
A 
B 
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Pseudomonas aeruginosa 
P. aeruginosa is a Gram-negative bacterium that is noted for its environmental 
versatility, its ability to cause disease in susceptible individuals, and its 
resistance to antibiotics.  The most serious condition caused by this bacterium 
is complications related to cystic fibrosis, a respiratory tract infection.  Cancer 
and burn patients also commonly suffer serious infections caused by this 
organism, as do other individuals with immune system deficiencies.  This 
organism’s remarkable ability to survive and adapt in many ecological niches, 
from water, to soil, plant and animal tissue, as well as its ability to survive on a 
range of organic compounds as food sources makes it a formidable cause of 
disease.   
P. aeruginosa is widely studied in the academic as well as pharmaceutical 
fraternity because of its uncanny ability to survive in diverse circumstances 
and its resistance to antibiotics.  The insights gained will be used to develop 
new antibacterial drugs to treat the infections caused by this bacterium. 
Until recently there was no gene homologous to either the Type I or Type II 
PanK in P. aeruginosa.  The only gene accounting for pantothenate kinase 
activity in this organism is the newly characterized CoaX-like PanK (Type III).  
As this organism poses such a threat in the health care industry it would make 
an extremely interesting subject for research. 
Our long-term goal will be to test inhibitors against all the organisms 
discussed thus far in the hopes of designing novel antibacterial agents that 
are highly specific and effective in targeting the Type III pantothenate kinase 
without harming the Type II PanK that is present in mammalian systems. 
6.2.6. Additional mutation studies 
After we have received the crystal structure of one of the Type III PanKs we 
will be able to identify additional amino acids in the active site of the enzyme 
responsible for activity.  From this information we will construct further 
mutants and test the consequence of the chosen mutations on the activity of 
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the protein.  This will further contribute to the complete characterization of this 
new pantothenate kinase. 
6.2.7. Drug Design 
As mentioned in 6.2.2 and 6.2.5 above, microbes are becoming increasingly 
resistant to antibiotics.  This is of great concern to the healthcare industry.  As 
bacteria evolve new means of defying the effect of antibiotics so we too have 
to develop novel inhibitors.  This current research into pantothenate kinase 
would go a long way to achieving this.   
CoA and its thioesters are inhibitors of the pantothenate kinase enzyme in all 
known analogues except the newly characterized S. aureus PanK and the 
CoaX-type pantothenate kinases.  Analogues of these CoA and CoA 
thioesters have been made and found to inhibit many of the Type I and II 
PanKs.  These results, however, are purely academic, as these CoA 
analogues cannot be transported over the cell membrane.  For this reason, 
the design of CoA antimetabolites must be based on pantothenic acid, the 
most advanced cell-permeable biosynthetic intermediate, or its precursors (9).   
We would like to conduct further inhibition studies with the CoaX-type PanK.  
Our aim would be to determine novel inhibitors based on the structure of 
pantothenate.  We would like to synthesize many of the analogues used in the 
studies conducted by Virga et al. (3) and use these substances as a stating 
block for our inhibitory studies.  The ideal inhibitor must be able to cross the 
cell membrane and be inhibitory to the pathogenic CoaX proteins only.  This 
would be the ideal candidate for further development as a species and 
enzyme specific drug.  This would truly be a breakthrough in so far as the 
design of novel inhibitors for pathogenic bacteria. 
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6.2.8.  The Role of CoaX Proteins 
The role of CoaX in organisms that possess another PanK analogue is 
enigmatic.  Does it serve as an additional, unregulated form of the enzyme, 
which is only active under certain conditions?  Or is it a latent enzyme activity, 
which has only been adapted to PanK activity at a later evolutionary stage?  
Does the CoaX form of the PanK possess unique characteristics that set it 
apart from the other two analogues of PanK and in so doing; make it ideally 
suited for adoption by mainly pathogenic organisms for the synthesis of 
coenzyme A?  We hope that further research into this protein will be able to 
answer some of these burning questions.   
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